CN115583970A - Method for preparing alpha- (hydroxy amino) diaryl phosphine oxide from nitrone - Google Patents
Method for preparing alpha- (hydroxy amino) diaryl phosphine oxide from nitrone Download PDFInfo
- Publication number
- CN115583970A CN115583970A CN202211267152.9A CN202211267152A CN115583970A CN 115583970 A CN115583970 A CN 115583970A CN 202211267152 A CN202211267152 A CN 202211267152A CN 115583970 A CN115583970 A CN 115583970A
- Authority
- CN
- China
- Prior art keywords
- nitrone
- compound
- solvent
- nmr
- alpha
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- -1 diaryl phosphine oxide Chemical compound 0.000 title claims abstract description 191
- 238000000034 method Methods 0.000 title claims abstract description 57
- SQDFHQJTAWCFIB-UHFFFAOYSA-N n-methylidenehydroxylamine Chemical compound ON=C SQDFHQJTAWCFIB-UHFFFAOYSA-N 0.000 title claims abstract description 37
- 125000002349 hydroxyamino group Chemical group [H]ON([H])[*] 0.000 title claims abstract description 28
- 239000002904 solvent Substances 0.000 claims abstract description 95
- 238000006243 chemical reaction Methods 0.000 claims abstract description 61
- 238000001953 recrystallisation Methods 0.000 claims abstract description 39
- 150000001875 compounds Chemical class 0.000 claims abstract description 31
- 239000002994 raw material Substances 0.000 claims abstract description 13
- 239000003814 drug Substances 0.000 claims abstract description 9
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims description 117
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 claims description 115
- 238000003756 stirring Methods 0.000 claims description 36
- 230000008569 process Effects 0.000 claims description 23
- 238000004537 pulping Methods 0.000 claims description 13
- 125000000217 alkyl group Chemical group 0.000 claims description 10
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 10
- ZUOUZKKEUPVFJK-UHFFFAOYSA-N diphenyl Chemical class C1=CC=CC=C1C1=CC=CC=C1 ZUOUZKKEUPVFJK-UHFFFAOYSA-N 0.000 claims description 8
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 8
- 125000002947 alkylene group Chemical group 0.000 claims description 6
- 238000004519 manufacturing process Methods 0.000 claims description 6
- 125000003118 aryl group Chemical group 0.000 claims description 5
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 5
- 238000002360 preparation method Methods 0.000 claims description 5
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 5
- 235000010290 biphenyl Nutrition 0.000 claims description 4
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 4
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims description 4
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 claims description 4
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims description 4
- 238000000967 suction filtration Methods 0.000 claims description 4
- JYVHOGDBFNJNMR-UHFFFAOYSA-N hexane;hydrate Chemical compound O.CCCCCC JYVHOGDBFNJNMR-UHFFFAOYSA-N 0.000 claims description 3
- 239000012535 impurity Substances 0.000 claims description 3
- 230000000259 anti-tumor effect Effects 0.000 claims description 2
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 2
- 239000004305 biphenyl Chemical class 0.000 claims description 2
- 125000002541 furyl group Chemical group 0.000 claims description 2
- 125000005059 halophenyl group Chemical group 0.000 claims description 2
- 238000010438 heat treatment Methods 0.000 claims description 2
- 125000001624 naphthyl group Chemical class 0.000 claims description 2
- GJVFBWCTGUSGDD-UHFFFAOYSA-L pentamethonium bromide Chemical compound [Br-].[Br-].C[N+](C)(C)CCCCC[N+](C)(C)C GJVFBWCTGUSGDD-UHFFFAOYSA-L 0.000 claims description 2
- 230000035484 reaction time Effects 0.000 claims description 2
- 125000001544 thienyl group Chemical group 0.000 claims description 2
- 230000005764 inhibitory process Effects 0.000 abstract description 5
- 206010028980 Neoplasm Diseases 0.000 abstract description 4
- 229910001392 phosphorus oxide Inorganic materials 0.000 abstract description 4
- 239000000758 substrate Substances 0.000 abstract description 4
- 230000001093 anti-cancer Effects 0.000 abstract description 3
- 239000003054 catalyst Substances 0.000 abstract description 3
- 229940079593 drug Drugs 0.000 abstract description 3
- 238000009776 industrial production Methods 0.000 abstract description 3
- 201000011510 cancer Diseases 0.000 abstract description 2
- 231100000135 cytotoxicity Toxicity 0.000 abstract description 2
- 230000003013 cytotoxicity Effects 0.000 abstract description 2
- 230000000694 effects Effects 0.000 abstract description 2
- 238000002474 experimental method Methods 0.000 abstract description 2
- 125000000524 functional group Chemical group 0.000 abstract description 2
- 230000002194 synthesizing effect Effects 0.000 abstract description 2
- 230000000144 pharmacologic effect Effects 0.000 abstract 1
- 238000005481 NMR spectroscopy Methods 0.000 description 97
- 239000000047 product Substances 0.000 description 69
- 230000015572 biosynthetic process Effects 0.000 description 59
- 238000003786 synthesis reaction Methods 0.000 description 59
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 39
- 229910052698 phosphorus Inorganic materials 0.000 description 39
- 239000011574 phosphorus Substances 0.000 description 39
- 239000011259 mixed solution Substances 0.000 description 37
- 238000012544 monitoring process Methods 0.000 description 37
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 32
- 239000012043 crude product Substances 0.000 description 32
- HYPPXZBJBPSRLK-UHFFFAOYSA-N diphenoxylate Chemical compound C1CC(C(=O)OCC)(C=2C=CC=CC=2)CCN1CCC(C#N)(C=1C=CC=CC=1)C1=CC=CC=C1 HYPPXZBJBPSRLK-UHFFFAOYSA-N 0.000 description 23
- 229960004192 diphenoxylate Drugs 0.000 description 23
- 239000003208 petroleum Substances 0.000 description 16
- 239000000243 solution Substances 0.000 description 9
- 210000004027 cell Anatomy 0.000 description 8
- 239000012044 organic layer Substances 0.000 description 7
- 150000003839 salts Chemical class 0.000 description 7
- YFPJFKYCVYXDJK-UHFFFAOYSA-N Diphenylphosphine oxide Chemical compound C=1C=CC=CC=1[P+](=O)C1=CC=CC=C1 YFPJFKYCVYXDJK-UHFFFAOYSA-N 0.000 description 6
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 4
- 238000001035 drying Methods 0.000 description 4
- 239000000706 filtrate Substances 0.000 description 4
- 238000001914 filtration Methods 0.000 description 4
- UBINNYMQZVKNFF-UHFFFAOYSA-N n-benzyl-1-phenylmethanimine oxide Chemical compound C=1C=CC=CC=1C=[N+]([O-])CC1=CC=CC=C1 UBINNYMQZVKNFF-UHFFFAOYSA-N 0.000 description 4
- 238000005935 nucleophilic addition reaction Methods 0.000 description 4
- UAOUIVVJBYDFKD-XKCDOFEDSA-N (1R,9R,10S,11R,12R,15S,18S,21R)-10,11,21-trihydroxy-8,8-dimethyl-14-methylidene-4-(prop-2-enylamino)-20-oxa-5-thia-3-azahexacyclo[9.7.2.112,15.01,9.02,6.012,18]henicosa-2(6),3-dien-13-one Chemical compound C([C@@H]1[C@@H](O)[C@@]23C(C1=C)=O)C[C@H]2[C@]12C(N=C(NCC=C)S4)=C4CC(C)(C)[C@H]1[C@H](O)[C@]3(O)OC2 UAOUIVVJBYDFKD-XKCDOFEDSA-N 0.000 description 3
- AOSZTAHDEDLTLQ-AZKQZHLXSA-N (1S,2S,4R,8S,9S,11S,12R,13S,19S)-6-[(3-chlorophenyl)methyl]-12,19-difluoro-11-hydroxy-8-(2-hydroxyacetyl)-9,13-dimethyl-6-azapentacyclo[10.8.0.02,9.04,8.013,18]icosa-14,17-dien-16-one Chemical compound C([C@@H]1C[C@H]2[C@H]3[C@]([C@]4(C=CC(=O)C=C4[C@@H](F)C3)C)(F)[C@@H](O)C[C@@]2([C@@]1(C1)C(=O)CO)C)N1CC1=CC=CC(Cl)=C1 AOSZTAHDEDLTLQ-AZKQZHLXSA-N 0.000 description 3
- ABJSOROVZZKJGI-OCYUSGCXSA-N (1r,2r,4r)-2-(4-bromophenyl)-n-[(4-chlorophenyl)-(2-fluoropyridin-4-yl)methyl]-4-morpholin-4-ylcyclohexane-1-carboxamide Chemical compound C1=NC(F)=CC(C(NC(=O)[C@H]2[C@@H](C[C@@H](CC2)N2CCOCC2)C=2C=CC(Br)=CC=2)C=2C=CC(Cl)=CC=2)=C1 ABJSOROVZZKJGI-OCYUSGCXSA-N 0.000 description 3
- SZUVGFMDDVSKSI-WIFOCOSTSA-N (1s,2s,3s,5r)-1-(carboxymethyl)-3,5-bis[(4-phenoxyphenyl)methyl-propylcarbamoyl]cyclopentane-1,2-dicarboxylic acid Chemical compound O=C([C@@H]1[C@@H]([C@](CC(O)=O)([C@H](C(=O)N(CCC)CC=2C=CC(OC=3C=CC=CC=3)=CC=2)C1)C(O)=O)C(O)=O)N(CCC)CC(C=C1)=CC=C1OC1=CC=CC=C1 SZUVGFMDDVSKSI-WIFOCOSTSA-N 0.000 description 3
- GHYOCDFICYLMRF-UTIIJYGPSA-N (2S,3R)-N-[(2S)-3-(cyclopenten-1-yl)-1-[(2R)-2-methyloxiran-2-yl]-1-oxopropan-2-yl]-3-hydroxy-3-(4-methoxyphenyl)-2-[[(2S)-2-[(2-morpholin-4-ylacetyl)amino]propanoyl]amino]propanamide Chemical compound C1(=CCCC1)C[C@@H](C(=O)[C@@]1(OC1)C)NC([C@H]([C@@H](C1=CC=C(C=C1)OC)O)NC([C@H](C)NC(CN1CCOCC1)=O)=O)=O GHYOCDFICYLMRF-UTIIJYGPSA-N 0.000 description 3
- WWTBZEKOSBFBEM-SPWPXUSOSA-N (2s)-2-[[2-benzyl-3-[hydroxy-[(1r)-2-phenyl-1-(phenylmethoxycarbonylamino)ethyl]phosphoryl]propanoyl]amino]-3-(1h-indol-3-yl)propanoic acid Chemical compound N([C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)O)C(=O)C(CP(O)(=O)[C@H](CC=1C=CC=CC=1)NC(=O)OCC=1C=CC=CC=1)CC1=CC=CC=C1 WWTBZEKOSBFBEM-SPWPXUSOSA-N 0.000 description 3
- STBLNCCBQMHSRC-BATDWUPUSA-N (2s)-n-[(3s,4s)-5-acetyl-7-cyano-4-methyl-1-[(2-methylnaphthalen-1-yl)methyl]-2-oxo-3,4-dihydro-1,5-benzodiazepin-3-yl]-2-(methylamino)propanamide Chemical compound O=C1[C@@H](NC(=O)[C@H](C)NC)[C@H](C)N(C(C)=O)C2=CC(C#N)=CC=C2N1CC1=C(C)C=CC2=CC=CC=C12 STBLNCCBQMHSRC-BATDWUPUSA-N 0.000 description 3
- QFLWZFQWSBQYPS-AWRAUJHKSA-N (3S)-3-[[(2S)-2-[[(2S)-2-[5-[(3aS,6aR)-2-oxo-1,3,3a,4,6,6a-hexahydrothieno[3,4-d]imidazol-4-yl]pentanoylamino]-3-methylbutanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-4-[1-bis(4-chlorophenoxy)phosphorylbutylamino]-4-oxobutanoic acid Chemical compound CCCC(NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@@H](NC(=O)CCCCC1SC[C@@H]2NC(=O)N[C@H]12)C(C)C)P(=O)(Oc1ccc(Cl)cc1)Oc1ccc(Cl)cc1 QFLWZFQWSBQYPS-AWRAUJHKSA-N 0.000 description 3
- IWZSHWBGHQBIML-ZGGLMWTQSA-N (3S,8S,10R,13S,14S,17S)-17-isoquinolin-7-yl-N,N,10,13-tetramethyl-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-3-amine Chemical compound CN(C)[C@H]1CC[C@]2(C)C3CC[C@@]4(C)[C@@H](CC[C@@H]4c4ccc5ccncc5c4)[C@@H]3CC=C2C1 IWZSHWBGHQBIML-ZGGLMWTQSA-N 0.000 description 3
- KQZLRWGGWXJPOS-NLFPWZOASA-N 1-[(1R)-1-(2,4-dichlorophenyl)ethyl]-6-[(4S,5R)-4-[(2S)-2-(hydroxymethyl)pyrrolidin-1-yl]-5-methylcyclohexen-1-yl]pyrazolo[3,4-b]pyrazine-3-carbonitrile Chemical compound ClC1=C(C=CC(=C1)Cl)[C@@H](C)N1N=C(C=2C1=NC(=CN=2)C1=CC[C@@H]([C@@H](C1)C)N1[C@@H](CCC1)CO)C#N KQZLRWGGWXJPOS-NLFPWZOASA-N 0.000 description 3
- WZZBNLYBHUDSHF-DHLKQENFSA-N 1-[(3s,4s)-4-[8-(2-chloro-4-pyrimidin-2-yloxyphenyl)-7-fluoro-2-methylimidazo[4,5-c]quinolin-1-yl]-3-fluoropiperidin-1-yl]-2-hydroxyethanone Chemical compound CC1=NC2=CN=C3C=C(F)C(C=4C(=CC(OC=5N=CC=CN=5)=CC=4)Cl)=CC3=C2N1[C@H]1CCN(C(=O)CO)C[C@@H]1F WZZBNLYBHUDSHF-DHLKQENFSA-N 0.000 description 3
- ONBQEOIKXPHGMB-VBSBHUPXSA-N 1-[2-[(2s,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]oxy-4,6-dihydroxyphenyl]-3-(4-hydroxyphenyl)propan-1-one Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1OC1=CC(O)=CC(O)=C1C(=O)CCC1=CC=C(O)C=C1 ONBQEOIKXPHGMB-VBSBHUPXSA-N 0.000 description 3
- UNILWMWFPHPYOR-KXEYIPSPSA-M 1-[6-[2-[3-[3-[3-[2-[2-[3-[[2-[2-[[(2r)-1-[[2-[[(2r)-1-[3-[2-[2-[3-[[2-(2-amino-2-oxoethoxy)acetyl]amino]propoxy]ethoxy]ethoxy]propylamino]-3-hydroxy-1-oxopropan-2-yl]amino]-2-oxoethyl]amino]-3-[(2r)-2,3-di(hexadecanoyloxy)propyl]sulfanyl-1-oxopropan-2-yl Chemical compound O=C1C(SCCC(=O)NCCCOCCOCCOCCCNC(=O)COCC(=O)N[C@@H](CSC[C@@H](COC(=O)CCCCCCCCCCCCCCC)OC(=O)CCCCCCCCCCCCCCC)C(=O)NCC(=O)N[C@H](CO)C(=O)NCCCOCCOCCOCCCNC(=O)COCC(N)=O)CC(=O)N1CCNC(=O)CCCCCN\1C2=CC=C(S([O-])(=O)=O)C=C2CC/1=C/C=C/C=C/C1=[N+](CC)C2=CC=C(S([O-])(=O)=O)C=C2C1 UNILWMWFPHPYOR-KXEYIPSPSA-M 0.000 description 3
- YSUIQYOGTINQIN-UZFYAQMZSA-N 2-amino-9-[(1S,6R,8R,9S,10R,15R,17R,18R)-8-(6-aminopurin-9-yl)-9,18-difluoro-3,12-dihydroxy-3,12-bis(sulfanylidene)-2,4,7,11,13,16-hexaoxa-3lambda5,12lambda5-diphosphatricyclo[13.2.1.06,10]octadecan-17-yl]-1H-purin-6-one Chemical compound NC1=NC2=C(N=CN2[C@@H]2O[C@@H]3COP(S)(=O)O[C@@H]4[C@@H](COP(S)(=O)O[C@@H]2[C@@H]3F)O[C@H]([C@H]4F)N2C=NC3=C2N=CN=C3N)C(=O)N1 YSUIQYOGTINQIN-UZFYAQMZSA-N 0.000 description 3
- TVTJUIAKQFIXCE-HUKYDQBMSA-N 2-amino-9-[(2R,3S,4S,5R)-4-fluoro-3-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-7-prop-2-ynyl-1H-purine-6,8-dione Chemical compound NC=1NC(C=2N(C(N(C=2N=1)[C@@H]1O[C@@H]([C@H]([C@H]1O)F)CO)=O)CC#C)=O TVTJUIAKQFIXCE-HUKYDQBMSA-N 0.000 description 3
- NPRYCHLHHVWLQZ-TURQNECASA-N 2-amino-9-[(2R,3S,4S,5R)-4-fluoro-3-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-7-prop-2-ynylpurin-8-one Chemical compound NC1=NC=C2N(C(N(C2=N1)[C@@H]1O[C@@H]([C@H]([C@H]1O)F)CO)=O)CC#C NPRYCHLHHVWLQZ-TURQNECASA-N 0.000 description 3
- QBWKPGNFQQJGFY-QLFBSQMISA-N 3-[(1r)-1-[(2r,6s)-2,6-dimethylmorpholin-4-yl]ethyl]-n-[6-methyl-3-(1h-pyrazol-4-yl)imidazo[1,2-a]pyrazin-8-yl]-1,2-thiazol-5-amine Chemical compound N1([C@H](C)C2=NSC(NC=3C4=NC=C(N4C=C(C)N=3)C3=CNN=C3)=C2)C[C@H](C)O[C@H](C)C1 QBWKPGNFQQJGFY-QLFBSQMISA-N 0.000 description 3
- 229940126657 Compound 17 Drugs 0.000 description 3
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- OPFJDXRVMFKJJO-ZHHKINOHSA-N N-{[3-(2-benzamido-4-methyl-1,3-thiazol-5-yl)-pyrazol-5-yl]carbonyl}-G-dR-G-dD-dD-dD-NH2 Chemical compound S1C(C=2NN=C(C=2)C(=O)NCC(=O)N[C@H](CCCN=C(N)N)C(=O)NCC(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC(O)=O)C(N)=O)=C(C)N=C1NC(=O)C1=CC=CC=C1 OPFJDXRVMFKJJO-ZHHKINOHSA-N 0.000 description 3
- LJOOWESTVASNOG-UFJKPHDISA-N [(1s,3r,4ar,7s,8s,8as)-3-hydroxy-8-[2-[(4r)-4-hydroxy-6-oxooxan-2-yl]ethyl]-7-methyl-1,2,3,4,4a,7,8,8a-octahydronaphthalen-1-yl] (2s)-2-methylbutanoate Chemical compound C([C@H]1[C@@H](C)C=C[C@H]2C[C@@H](O)C[C@@H]([C@H]12)OC(=O)[C@@H](C)CC)CC1C[C@@H](O)CC(=O)O1 LJOOWESTVASNOG-UFJKPHDISA-N 0.000 description 3
- LNUFLCYMSVYYNW-ZPJMAFJPSA-N [(2r,3r,4s,5r,6r)-2-[(2r,3r,4s,5r,6r)-6-[(2r,3r,4s,5r,6r)-6-[(2r,3r,4s,5r,6r)-6-[[(3s,5s,8r,9s,10s,13r,14s,17r)-10,13-dimethyl-17-[(2r)-6-methylheptan-2-yl]-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-3-yl]oxy]-4,5-disulfo Chemical compound O([C@@H]1[C@@H](COS(O)(=O)=O)O[C@@H]([C@@H]([C@H]1OS(O)(=O)=O)OS(O)(=O)=O)O[C@@H]1[C@@H](COS(O)(=O)=O)O[C@@H]([C@@H]([C@H]1OS(O)(=O)=O)OS(O)(=O)=O)O[C@@H]1[C@@H](COS(O)(=O)=O)O[C@H]([C@@H]([C@H]1OS(O)(=O)=O)OS(O)(=O)=O)O[C@@H]1C[C@@H]2CC[C@H]3[C@@H]4CC[C@@H]([C@]4(CC[C@@H]3[C@@]2(C)CC1)C)[C@H](C)CCCC(C)C)[C@H]1O[C@H](COS(O)(=O)=O)[C@@H](OS(O)(=O)=O)[C@H](OS(O)(=O)=O)[C@H]1OS(O)(=O)=O LNUFLCYMSVYYNW-ZPJMAFJPSA-N 0.000 description 3
- SMNRFWMNPDABKZ-WVALLCKVSA-N [[(2R,3S,4R,5S)-5-(2,6-dioxo-3H-pyridin-3-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl] [[[(2R,3S,4S,5R,6R)-4-fluoro-3,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-hydroxyphosphoryl]oxy-hydroxyphosphoryl] hydrogen phosphate Chemical compound OC[C@H]1O[C@H](OP(O)(=O)OP(O)(=O)OP(O)(=O)OP(O)(=O)OC[C@H]2O[C@H]([C@H](O)[C@@H]2O)C2C=CC(=O)NC2=O)[C@H](O)[C@@H](F)[C@@H]1O SMNRFWMNPDABKZ-WVALLCKVSA-N 0.000 description 3
- WREOTYWODABZMH-DTZQCDIJSA-N [[(2r,3s,4r,5r)-3,4-dihydroxy-5-[2-oxo-4-(2-phenylethoxyamino)pyrimidin-1-yl]oxolan-2-yl]methoxy-hydroxyphosphoryl] phosphono hydrogen phosphate Chemical compound O[C@@H]1[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O[C@H]1N(C=C\1)C(=O)NC/1=N\OCCC1=CC=CC=C1 WREOTYWODABZMH-DTZQCDIJSA-N 0.000 description 3
- 238000002835 absorbance Methods 0.000 description 3
- XRWSZZJLZRKHHD-WVWIJVSJSA-N asunaprevir Chemical compound O=C([C@@H]1C[C@H](CN1C(=O)[C@@H](NC(=O)OC(C)(C)C)C(C)(C)C)OC1=NC=C(C2=CC=C(Cl)C=C21)OC)N[C@]1(C(=O)NS(=O)(=O)C2CC2)C[C@H]1C=C XRWSZZJLZRKHHD-WVWIJVSJSA-N 0.000 description 3
- KGNDCEVUMONOKF-UGPLYTSKSA-N benzyl n-[(2r)-1-[(2s,4r)-2-[[(2s)-6-amino-1-(1,3-benzoxazol-2-yl)-1,1-dihydroxyhexan-2-yl]carbamoyl]-4-[(4-methylphenyl)methoxy]pyrrolidin-1-yl]-1-oxo-4-phenylbutan-2-yl]carbamate Chemical compound C1=CC(C)=CC=C1CO[C@H]1CN(C(=O)[C@@H](CCC=2C=CC=CC=2)NC(=O)OCC=2C=CC=CC=2)[C@H](C(=O)N[C@@H](CCCCN)C(O)(O)C=2OC3=CC=CC=C3N=2)C1 KGNDCEVUMONOKF-UGPLYTSKSA-N 0.000 description 3
- 125000004432 carbon atom Chemical group C* 0.000 description 3
- 229940125904 compound 1 Drugs 0.000 description 3
- 229940125773 compound 10 Drugs 0.000 description 3
- 229940125797 compound 12 Drugs 0.000 description 3
- 229940126543 compound 14 Drugs 0.000 description 3
- 229940125758 compound 15 Drugs 0.000 description 3
- 229940126142 compound 16 Drugs 0.000 description 3
- 229940125782 compound 2 Drugs 0.000 description 3
- 229940125810 compound 20 Drugs 0.000 description 3
- 229940126086 compound 21 Drugs 0.000 description 3
- 229940126208 compound 22 Drugs 0.000 description 3
- 229940125833 compound 23 Drugs 0.000 description 3
- 229940125961 compound 24 Drugs 0.000 description 3
- 229940125846 compound 25 Drugs 0.000 description 3
- 229940125851 compound 27 Drugs 0.000 description 3
- 229940127204 compound 29 Drugs 0.000 description 3
- 229940126214 compound 3 Drugs 0.000 description 3
- 229940125877 compound 31 Drugs 0.000 description 3
- 229940125878 compound 36 Drugs 0.000 description 3
- 229940125898 compound 5 Drugs 0.000 description 3
- JAXFJECJQZDFJS-XHEPKHHKSA-N gtpl8555 Chemical compound OC(=O)C[C@H](N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N1CCC[C@@H]1C(=O)N[C@H](B1O[C@@]2(C)[C@H]3C[C@H](C3(C)C)C[C@H]2O1)CCC1=CC=C(F)C=C1 JAXFJECJQZDFJS-XHEPKHHKSA-N 0.000 description 3
- ZLVXBBHTMQJRSX-VMGNSXQWSA-N jdtic Chemical compound C1([C@]2(C)CCN(C[C@@H]2C)C[C@H](C(C)C)NC(=O)[C@@H]2NCC3=CC(O)=CC=C3C2)=CC=CC(O)=C1 ZLVXBBHTMQJRSX-VMGNSXQWSA-N 0.000 description 3
- 230000007246 mechanism Effects 0.000 description 3
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 3
- 238000001308 synthesis method Methods 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- ASGMFNBUXDJWJJ-JLCFBVMHSA-N (1R,3R)-3-[[3-bromo-1-[4-(5-methyl-1,3,4-thiadiazol-2-yl)phenyl]pyrazolo[3,4-d]pyrimidin-6-yl]amino]-N,1-dimethylcyclopentane-1-carboxamide Chemical compound BrC1=NN(C2=NC(=NC=C21)N[C@H]1C[C@@](CC1)(C(=O)NC)C)C1=CC=C(C=C1)C=1SC(=NN=1)C ASGMFNBUXDJWJJ-JLCFBVMHSA-N 0.000 description 2
- IUSARDYWEPUTPN-OZBXUNDUSA-N (2r)-n-[(2s,3r)-4-[[(4s)-6-(2,2-dimethylpropyl)spiro[3,4-dihydropyrano[2,3-b]pyridine-2,1'-cyclobutane]-4-yl]amino]-3-hydroxy-1-[3-(1,3-thiazol-2-yl)phenyl]butan-2-yl]-2-methoxypropanamide Chemical compound C([C@H](NC(=O)[C@@H](C)OC)[C@H](O)CN[C@@H]1C2=CC(CC(C)(C)C)=CN=C2OC2(CCC2)C1)C(C=1)=CC=CC=1C1=NC=CS1 IUSARDYWEPUTPN-OZBXUNDUSA-N 0.000 description 2
- 206010006187 Breast cancer Diseases 0.000 description 2
- 208000026310 Breast neoplasm Diseases 0.000 description 2
- KLWPJMFMVPTNCC-UHFFFAOYSA-N Camptothecin Natural products CCC1(O)C(=O)OCC2=C1C=C3C4Nc5ccccc5C=C4CN3C2=O KLWPJMFMVPTNCC-UHFFFAOYSA-N 0.000 description 2
- 229940126639 Compound 33 Drugs 0.000 description 2
- 229940127007 Compound 39 Drugs 0.000 description 2
- YLQBMQCUIZJEEH-UHFFFAOYSA-N Furan Chemical compound C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 2
- PNUZDKCDAWUEGK-CYZMBNFOSA-N Sitafloxacin Chemical compound C([C@H]1N)N(C=2C(=C3C(C(C(C(O)=O)=CN3[C@H]3[C@H](C3)F)=O)=CC=2F)Cl)CC11CC1 PNUZDKCDAWUEGK-CYZMBNFOSA-N 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 230000000840 anti-viral effect Effects 0.000 description 2
- 239000002246 antineoplastic agent Substances 0.000 description 2
- 125000004429 atom Chemical group 0.000 description 2
- VSJKWCGYPAHWDS-FQEVSTJZSA-N camptothecin Chemical compound C1=CC=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 VSJKWCGYPAHWDS-FQEVSTJZSA-N 0.000 description 2
- 229940127093 camptothecin Drugs 0.000 description 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 2
- 229940125807 compound 37 Drugs 0.000 description 2
- 229940127573 compound 38 Drugs 0.000 description 2
- VSJKWCGYPAHWDS-UHFFFAOYSA-N dl-camptothecin Natural products C1=CC=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)C5(O)CC)C4=NC2=C1 VSJKWCGYPAHWDS-UHFFFAOYSA-N 0.000 description 2
- 229910052736 halogen Inorganic materials 0.000 description 2
- 150000002367 halogens Chemical class 0.000 description 2
- 238000005927 hydrophosphonylation reaction Methods 0.000 description 2
- 230000005918 in vitro anti-tumor Effects 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 150000002500 ions Chemical class 0.000 description 2
- 150000007522 mineralic acids Chemical class 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- PIDFDZJZLOTZTM-KHVQSSSXSA-N ombitasvir Chemical compound COC(=O)N[C@@H](C(C)C)C(=O)N1CCC[C@H]1C(=O)NC1=CC=C([C@H]2N([C@@H](CC2)C=2C=CC(NC(=O)[C@H]3N(CCC3)C(=O)[C@@H](NC(=O)OC)C(C)C)=CC=2)C=2C=CC(=CC=2)C(C)(C)C)C=C1 PIDFDZJZLOTZTM-KHVQSSSXSA-N 0.000 description 2
- 150000007524 organic acids Chemical class 0.000 description 2
- 235000005985 organic acids Nutrition 0.000 description 2
- 150000002903 organophosphorus compounds Chemical class 0.000 description 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- 239000000376 reactant Substances 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 238000006467 substitution reaction Methods 0.000 description 2
- VSAISIQCTGDGPU-UHFFFAOYSA-N tetraphosphorus hexaoxide Chemical compound O1P(O2)OP3OP1OP2O3 VSAISIQCTGDGPU-UHFFFAOYSA-N 0.000 description 2
- 210000004881 tumor cell Anatomy 0.000 description 2
- FYVRCXABOYBHKY-GSDHBNRESA-N (2s,3s,4s)-1-oxido-3,4-bis(phenylmethoxy)-2-(phenylmethoxymethyl)-3,4-dihydro-2h-pyrrol-1-ium Chemical compound O([C@H]1C=[N+]([C@H]([C@@H]1OCC=1C=CC=CC=1)COCC=1C=CC=CC=1)[O-])CC1=CC=CC=C1 FYVRCXABOYBHKY-GSDHBNRESA-N 0.000 description 1
- 238000001644 13C nuclear magnetic resonance spectroscopy Methods 0.000 description 1
- AXQPWUAAOXVGOR-UHFFFAOYSA-N 2-oxido-3,4-dihydroisoquinolin-2-ium Chemical compound C1=CC=C2CC[N+]([O-])=CC2=C1 AXQPWUAAOXVGOR-UHFFFAOYSA-N 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical group [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- 208000010507 Adenocarcinoma of Lung Diseases 0.000 description 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
- COVZYZSDYWQREU-UHFFFAOYSA-N Busulfan Chemical compound CS(=O)(=O)OCCCCOS(C)(=O)=O COVZYZSDYWQREU-UHFFFAOYSA-N 0.000 description 1
- REJNKDCFNDWJPK-UHFFFAOYSA-N CC=1C=C(C=C(C1)C)[PH2]=O Chemical compound CC=1C=C(C=C(C1)C)[PH2]=O REJNKDCFNDWJPK-UHFFFAOYSA-N 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- HGLLFQYGKHVMKF-UHFFFAOYSA-N N-benzyl-1-(2-chlorophenyl)methanimine oxide Chemical compound C=1C=CC=C(Cl)C=1C=[N+]([O-])CC1=CC=CC=C1 HGLLFQYGKHVMKF-UHFFFAOYSA-N 0.000 description 1
- NVCVZFZHNVDDKL-UHFFFAOYSA-N N-benzyl-1-(2-methoxyphenyl)methanimine oxide Chemical compound COc1ccccc1C=[N+]([O-])Cc1ccccc1 NVCVZFZHNVDDKL-UHFFFAOYSA-N 0.000 description 1
- WCSLRFXLFHOEHJ-UHFFFAOYSA-N N-benzyl-1-(3-methoxyphenyl)methanimine oxide Chemical compound COc1cccc(C=[N+]([O-])Cc2ccccc2)c1 WCSLRFXLFHOEHJ-UHFFFAOYSA-N 0.000 description 1
- ZGXKQEBDSZYZKG-UHFFFAOYSA-N N-benzyl-1-(4-nitrophenyl)methanimine oxide Chemical compound C=1C=C([N+]([O-])=O)C=CC=1C=[N+]([O-])CC1=CC=CC=C1 ZGXKQEBDSZYZKG-UHFFFAOYSA-N 0.000 description 1
- SOVZPSHUFJLSRK-UHFFFAOYSA-N N-benzyl-1-[4-(trifluoromethyl)phenyl]methanimine oxide Chemical compound C=1C=C(C(F)(F)F)C=CC=1C=[N+]([O-])CC1=CC=CC=C1 SOVZPSHUFJLSRK-UHFFFAOYSA-N 0.000 description 1
- XYFCBTPGUUZFHI-UHFFFAOYSA-N Phosphine Natural products P XYFCBTPGUUZFHI-UHFFFAOYSA-N 0.000 description 1
- 206010060862 Prostate cancer Diseases 0.000 description 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 1
- 208000005718 Stomach Neoplasms Diseases 0.000 description 1
- KGNCPCNAWUTBGB-UHFFFAOYSA-N [P].C1(=CC=CC=C1)OC1=CC=CC=C1 Chemical compound [P].C1(=CC=CC=C1)OC1=CC=CC=C1 KGNCPCNAWUTBGB-UHFFFAOYSA-N 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 239000003905 agrochemical Substances 0.000 description 1
- 125000001931 aliphatic group Chemical group 0.000 description 1
- 150000001336 alkenes Chemical class 0.000 description 1
- 150000001345 alkine derivatives Chemical class 0.000 description 1
- 125000003545 alkoxy group Chemical group 0.000 description 1
- 125000003368 amide group Chemical group 0.000 description 1
- 150000001450 anions Chemical class 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 229940041181 antineoplastic drug Drugs 0.000 description 1
- 239000003443 antiviral agent Substances 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid group Chemical group C(C1=CC=CC=C1)(=O)O WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
- 229910052794 bromium Inorganic materials 0.000 description 1
- 230000003197 catalytic effect Effects 0.000 description 1
- 150000001768 cations Chemical class 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- 239000000460 chlorine Substances 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 210000000448 cultured tumor cell Anatomy 0.000 description 1
- 125000000753 cycloalkyl group Chemical group 0.000 description 1
- 231100000263 cytotoxicity test Toxicity 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 238000004925 denaturation Methods 0.000 description 1
- 230000036425 denaturation Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- USIUVYZYUHIAEV-UHFFFAOYSA-N diphenyl ether Chemical compound C=1C=CC=CC=1OC1=CC=CC=C1 USIUVYZYUHIAEV-UHFFFAOYSA-N 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 239000003063 flame retardant Substances 0.000 description 1
- 229910052731 fluorine Inorganic materials 0.000 description 1
- 239000011737 fluorine Substances 0.000 description 1
- 206010017758 gastric cancer Diseases 0.000 description 1
- 230000009036 growth inhibition Effects 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 125000001475 halogen functional group Chemical group 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 239000004009 herbicide Substances 0.000 description 1
- 125000004356 hydroxy functional group Chemical group O* 0.000 description 1
- UWYVPFMHMJIBHE-OWOJBTEDSA-N hydroxymaleic acid group Chemical group O/C(/C(=O)O)=C/C(=O)O UWYVPFMHMJIBHE-OWOJBTEDSA-N 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 150000007529 inorganic bases Chemical class 0.000 description 1
- QWXYZCJEXYQNEI-OSZHWHEXSA-N intermediate I Chemical compound COC(=O)[C@@]1(C=O)[C@H]2CC=[N+](C\C2=C\C)CCc2c1[nH]c1ccccc21 QWXYZCJEXYQNEI-OSZHWHEXSA-N 0.000 description 1
- 239000012948 isocyanate Substances 0.000 description 1
- 150000002513 isocyanates Chemical class 0.000 description 1
- 150000002540 isothiocyanates Chemical class 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 201000007270 liver cancer Diseases 0.000 description 1
- 208000014018 liver neoplasm Diseases 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 201000005249 lung adenocarcinoma Diseases 0.000 description 1
- 201000005202 lung cancer Diseases 0.000 description 1
- 208000020816 lung neoplasm Diseases 0.000 description 1
- 238000013507 mapping Methods 0.000 description 1
- VMGAPWLDMVPYIA-HIDZBRGKSA-N n'-amino-n-iminomethanimidamide Chemical compound N\N=C\N=N VMGAPWLDMVPYIA-HIDZBRGKSA-N 0.000 description 1
- MWBFZFCMKNEMFL-UHFFFAOYSA-N n-benzyl-1-(4-chlorophenyl)methanimine oxide Chemical compound C=1C=C(Cl)C=CC=1C=[N+]([O-])CC1=CC=CC=C1 MWBFZFCMKNEMFL-UHFFFAOYSA-N 0.000 description 1
- UNSQOQPECTXHPU-UHFFFAOYSA-N n-benzyl-1-(4-methoxyphenyl)methanimine oxide Chemical compound C1=CC(OC)=CC=C1C=[N+]([O-])CC1=CC=CC=C1 UNSQOQPECTXHPU-UHFFFAOYSA-N 0.000 description 1
- JHMNHVYEVBXAQM-UHFFFAOYSA-N n-benzyl-1-cyclohexylmethanimine oxide Chemical compound C1CCCCC1C=[N+]([O-])CC1=CC=CC=C1 JHMNHVYEVBXAQM-UHFFFAOYSA-N 0.000 description 1
- SBIPPLAPIJMTMP-UHFFFAOYSA-N n-benzyl-2-methylpropan-1-imine oxide Chemical compound CC(C)C=[N+]([O-])CC1=CC=CC=C1 SBIPPLAPIJMTMP-UHFFFAOYSA-N 0.000 description 1
- RNLZGTIIHIKFGT-UHFFFAOYSA-N n-benzylbutan-1-imine oxide Chemical compound CCCC=[N+]([O-])CC1=CC=CC=C1 RNLZGTIIHIKFGT-UHFFFAOYSA-N 0.000 description 1
- ARAZMMHSKXHHPW-UHFFFAOYSA-N n-benzylpropan-1-imine oxide Chemical compound CCC=[N+]([O-])CC1=CC=CC=C1 ARAZMMHSKXHHPW-UHFFFAOYSA-N 0.000 description 1
- QZJWIZSRELSJQP-UHFFFAOYSA-N n-methyl-1-(4-methylphenyl)methanimine oxide Chemical compound CC1=CC=C(C=[N+](C)[O-])C=C1 QZJWIZSRELSJQP-UHFFFAOYSA-N 0.000 description 1
- AKVBBQCAQAJLKM-UHFFFAOYSA-N n-methyl-1-phenylmethanimine oxide Chemical compound C[N+]([O-])=CC1=CC=CC=C1 AKVBBQCAQAJLKM-UHFFFAOYSA-N 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- 239000002547 new drug Substances 0.000 description 1
- 125000004433 nitrogen atom Chemical group N* 0.000 description 1
- 230000000269 nucleophilic effect Effects 0.000 description 1
- 150000007530 organic bases Chemical class 0.000 description 1
- 239000012074 organic phase Substances 0.000 description 1
- 230000000737 periodic effect Effects 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 239000000575 pesticide Substances 0.000 description 1
- WLJVXDMOQOGPHL-UHFFFAOYSA-N phenylacetic acid Chemical compound OC(=O)CC1=CC=CC=C1 WLJVXDMOQOGPHL-UHFFFAOYSA-N 0.000 description 1
- 229910000073 phosphorus hydride Inorganic materials 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 238000003672 processing method Methods 0.000 description 1
- 125000006239 protecting group Chemical group 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- BOLDJAUMGUJJKM-LSDHHAIUSA-N renifolin D Natural products CC(=C)[C@@H]1Cc2c(O)c(O)ccc2[C@H]1CC(=O)c3ccc(O)cc3O BOLDJAUMGUJJKM-LSDHHAIUSA-N 0.000 description 1
- 230000027756 respiratory electron transport chain Effects 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 238000007614 solvation Methods 0.000 description 1
- 201000011549 stomach cancer Diseases 0.000 description 1
- 238000010189 synthetic method Methods 0.000 description 1
- 125000003831 tetrazolyl group Chemical group 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 230000003313 weakening effect Effects 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/28—Phosphorus compounds with one or more P—C bonds
- C07F9/50—Organo-phosphines
- C07F9/53—Organo-phosphine oxides; Organo-phosphine thioxides
- C07F9/5333—Arylalkane phosphine oxides or thioxides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/28—Phosphorus compounds with one or more P—C bonds
- C07F9/50—Organo-phosphines
- C07F9/53—Organo-phosphine oxides; Organo-phosphine thioxides
- C07F9/5325—Aromatic phosphine oxides or thioxides (P-C aromatic linkage)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/553—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having one nitrogen atom as the only ring hetero atom
- C07F9/572—Five-membered rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/553—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having one nitrogen atom as the only ring hetero atom
- C07F9/576—Six-membered rings
- C07F9/59—Hydrogenated pyridine rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/553—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having one nitrogen atom as the only ring hetero atom
- C07F9/576—Six-membered rings
- C07F9/62—Isoquinoline or hydrogenated isoquinoline ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/655—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having oxygen atoms, with or without sulfur, selenium, or tellurium atoms, as the only ring hetero atoms
- C07F9/65515—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having oxygen atoms, with or without sulfur, selenium, or tellurium atoms, as the only ring hetero atoms the oxygen atom being part of a five-membered ring
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
Abstract
The invention belongs to the technical field of medicines, and relates to a method for preparing alpha- (hydroxy amino) diaryl phosphine oxide from nitrone. The invention establishes a simple method for synthesizing alpha- (hydroxyl amino) phosphine oxide without catalyst by taking nitrone and diaryl phosphorus oxide as raw materials under mild conditions. The reaction of the invention can be carried out in the absence of solvent or in a low-added solvent, the reaction atom has high economy, can be purified by a simple recrystallization method, shows wide substrate range and good functional group tolerance, and has the characteristics of cheap and easily obtained raw materials, high yield, simple and convenient operation, high safety, no pollution, wide substrate application range and suitability for industrial production. Pharmacological activity experiments show that the compounds have good cancer inhibition activity, no obvious cytotoxicity and potential medicinal value, and are expected to be used for preparing various anti-cancer medicaments.
Description
Technical Field
The invention belongs to the technical field of medicines, and particularly relates to a method for preparing alpha- (hydroxy amino) diaryl phosphine oxide from nitrone.
Background
Organophosphorus compounds are of considerable importance as important compounds for organic synthesis in the fields of medicinal chemistry, agricultural industry and the like, for example: pharmaceuticals (antiviral and anticancer agents), agrochemicals (pesticides and herbicides), catalytic ligands and industrial additives (e.g. polymers and flame retardants). The classical synthesis processes of these compounds are affected by the use of stoichiometric additives, the need for protecting groups, and poor functional group tolerance. This prompted studies to add P (O) -H bonds directly to C = N unsaturated bonds, which is likely to have 100% atomic efficiency.
The alpha- (hydroxyl amino) phosphine oxide has not been synthesized in large quantity by people, may have unique biological activity and medicinal value, and can be used as an intermediate for synthesizing alpha-aminophosphine compounds, and the alpha-aminophosphine compounds have antiviral, antibacterial, anticancer and enzyme inhibition activities. Therefore, the organic phosphorus oxide has important application value in the fields of natural product synthesis, chemical industry, medicine and the like as an important organic synthesis intermediate, and researches on developing a green, efficient and economic synthesis method of the organic phosphorus oxide are widely concerned by researchers in related fields.
In the prior art, methods of adding P (O) -H bonds to alkenes or alkynes without adding solvents or catalysts have been developed. The prior art also discloses a catalyst-free, low-solvent process for the hydrophosphonylation of isocyanates and isothiocyanates. However, no method has been studied for adding a P (O) -H bond to an unsaturated C = N double bond of nitrone. Therefore, the development of an economical, environment-friendly and efficient synthetic method is of great significance, and the structural diversity of the organic phosphine compound is increased.
Malignant tumors are serious diseases threatening human health and life, and are one of the main causes of death in china. The search and discovery of new drugs for the treatment and prevention of tumors is also a major issue currently facing. The research on the antitumor activity of the alpha- (hydroxyl amino) phosphine oxide is not reported at present.
Disclosure of Invention
Based on the technical problems, the invention aims to provide a green synthesis method of alpha- (hydroxy amino) diaryl phosphine oxide, so as to prepare a novel organic phosphorus compound, and the method has the characteristics of cheap and easily obtained raw materials, high yield, simple and convenient operation, high safety, no pollution, wide substrate application range and suitability for industrial production.
The compound prepared by the invention shows good results in-vitro antitumor activity tests, and has no obvious cytotoxicity.
According to the method for preparing alpha- (hydroxy amino) diaryl phosphine oxide from nitrone, nitrone shown as a formula (2) and diaryl phosphine oxide shown as a formula (3) are used as raw materials and react under the heating condition to obtain alpha- (hydroxy amino) diaryl phosphine oxide shown as a formula (1),
wherein R is 1 Is selected from C 1 -C 10 Alkyl, furyl, thienyl, C 5 -C 6 One of an alkylene ring, a phenyl group or an aromatic group,
R 2 is selected from C 1 -C 10 Alkyl of (C) 5 -C 6 One of an alkylene ring, a substituted or unsubstituted phenyl;
R 3 、R 4 each independently selected from phenyl and aryl.
The term "alkyl" refers to a saturated or unsaturated aliphatic hydrocarbon group, which may be straight or branched and has 1 to 10 atoms in the chain. Preferred alkyl groups have 1 to 6 carbon atoms in the chain. "branched" means that one or more lower alkyl groups such as methyl, ethyl or propyl are attached to a linear alkyl chain. "lower alkyl" means having 1 to 4 carbon atoms in the chain, which may be straight or branched. The alkyl group may be substituted with one or more "alkyl substituents" which may be the same or different, including, for example, halogen, cycloalkyl, hydroxy, alkoxy, amino, amido, arylamido, carboxy.
A process for preparing alpha- (hydroxyamino) diarylphosphine oxides from nitrones according to an embodiment of the present invention, R 1 Selected from ethyl, propyl, isopropyl, butyl, isobutyl, cyclohexyl, halophenyl, alkyl-substituted phenyl, methoxy-substituted phenyl, methylamino-substituted phenyl, acetoxy-substituted phenyl, naphthyl, or biphenyl.
The term "halo" means substituted by an atom of a halogen in the periodic table of elements, and specifically includes fluorine, chlorine, bromine and iodine atoms.
A process for preparing alpha- (hydroxyamino) diarylphosphine oxides from nitrones according to an embodiment of the present invention, R 2 Selected from ethyl, propyl, isopropyl, butyl, isobutyl, cyclohexyl, phenyl or benzyl.
Preferably, R 1 、R 2 Each independently selected from C 5 -C 6 An alkylene ring.
The method for preparing alpha- (hydroxyamino) diarylphosphine oxide from nitrone according to the embodiment of the present invention is applicable as long as the amount of raw material capable of promoting the above nucleophilic addition reaction is available, and in order to improve the reaction yield and the raw material utilization rate, the ratio of nitrone to diarylphosphine oxide compound is 1:1-2, preferably, the ratio of nitrone to diarylphosphine oxide compound is 1.5.
In the method for preparing alpha- (hydroxyamino) diarylphosphine oxide from nitrone according to the embodiment of the present invention, it is possible to use the solvent capable of promoting the above nucleophilic addition reaction without causing denaturation of the raw material and the product, and the amount of the solvent is effective for the reaction, and the reaction is promoted, and in one embodiment, the nitrone and the diarylphosphine oxide compound are used as the raw material, and water or n-hexane is used as the solvent, preferably, the amount of the water may be 50 to 100 times that of the nitrone, and the amount of the n-hexane may be 50 to 100 times that of the nitrone.
The method for preparing alpha- (hydroxyamino) diarylphosphine oxide from nitrone according to the embodiment of the present invention has a reaction time of 1-3 hours.
According to the method for preparing alpha- (hydroxyl amino) diaryl phosphine oxide from nitrone, the nitrone shown as the formula (2) and the diaryl phosphine oxide compound shown as the formula (3) are used as raw materials and react at the temperature of 60-90 ℃.
According to the method for preparing alpha- (hydroxyamino) diarylphosphine oxide from nitrone of the embodiment of the present invention, alpha- (hydroxyamino) diarylphosphine oxide represented by formula (1) is obtained and then purified, and the purification steps are: removing solvent, and purifying by recrystallization or pulping to obtain pure product.
Preferably, the step of recrystallization is: dissolving the product by using ethyl acetate, separating out the product by using normal hexane, and performing suction filtration to obtain a pure product;
the pulping method comprises the following steps: firstly, adding normal hexane into the product, quickly stirring to dissolve impurities, and carrying out suction filtration to obtain a pure product.
In the preparation method, the recrystallization solvent consists of 1-5 parts by volume of n-hexane and 1 part by volume of ethyl acetate. The normal hexane can be replaced by petroleum ether, the product and other impurities can be effectively separated through recrystallization, and the yield is extremely high.
The invention also provides the application of the alpha- (hydroxyl amino) diaryl phosphine oxide in preparing antitumor drugs. The medicament comprises alpha- (hydroxyamino) diarylphosphine oxide, pharmaceutically acceptable salts of alpha- (hydroxyamino) diarylphosphine oxide.
The term "pharmaceutically acceptable salt" refers to a salt that retains the biological effectiveness and properties of the compounds of the present invention and is not biologically or otherwise undesirable. In many examples, the compounds of the present invention may form acid and/or base salts by virtue of the presence of amino and/or carboxyl groups or similar groups. Pharmaceutically acceptable acid addition salts may be prepared from inorganic or organic acids, while pharmaceutically acceptable base addition salts may be prepared from inorganic or organic bases. For example, such salts include those derived from inorganic acids such as hydrochloric, hydrobromic, sulfuric, sulfamic, phosphoric, nitric and the like, as well as from organic acids such as acetic, propionic, succinic, glycolic, stearic, lactic, malic, tartaric, citric, ascorbic, pamoic, maleic, hydroxymaleic, phenylacetic, glutamic, benzoic, salicylic, sulfanilic, fumaric, methanesulfonic, toluenesulfonic and the like.
Wherein the tumor refers to solid tumor, including breast cancer, prostatic cancer, lung cancer, gastric cancer, liver cancer and the like.
The invention has the beneficial effects that:
the preparation method of alpha- (hydroxyl amino) diaryl phosphine oxide provided by the invention is to mix aromatic or aliphatic nitrone derivative and diaryl phosphorus oxide in a solvent and then carry out nucleophilic addition reaction to realize the synthesis of alpha- (hydroxyl amino) diaryl phosphine oxide.
The preparation method can be carried out under the conditions of air and no solvent, and the reaction condition is mild and easy to control; the obtained raw materials are easy to obtain, and the application range of the substrate is wide; the reaction process can be carried out under the condition of no catalyst; the reaction specificity is strong, the yield can be higher in a shorter time, the post-treatment is simple and convenient, and the method is green and environment-friendly and is suitable for large-scale industrial production.
Drawings
In order to more clearly illustrate the embodiments of the present invention or the technical solutions in the prior art, the drawings used in the description of the embodiments or the prior art will be briefly described below, it is obvious that the drawings in the following description are only some embodiments of the present invention, and for those skilled in the art, other drawings can be obtained according to the drawings without creative efforts.
FIG. 1 is a schematic diagram of the mechanism for preparing alpha- (hydroxyamino) diarylphosphine oxides by the process of the present invention.
Detailed Description
In order to make the objects, technical solutions and advantages of the present invention more apparent, the technical solutions of the present invention will be described in detail below. It is to be understood that the described embodiments are merely exemplary of the invention, and not restrictive of the full scope of the invention. All other embodiments, which can be derived by a person skilled in the art from the examples given herein without making any creative effort, shall fall within the protection scope of the present invention.
The reaction formula for preparing alpha- (hydroxy amino) diaryl phosphine oxide of the invention is as follows:
as shown in formula (5):
the reaction mechanism is shown in FIG. 1, initially, the proton on the diaryl phosphine oxide 2 is transferred and combined with the oxyanion on the nitrone 1 to form an intermediate I and a nucleophilic moiety II, wherein N is in the form of cation and P is in the form of anion. And secondly, the P negative ions attack carbon atoms of carbon-nitrogen double bonds in II, so that the whole electrons of the carbon-nitrogen double bonds are transferred to N to generate the required hydrophosphonylation product 3. In addition, under acidic conditions, the diarylphosphine oxide is less likely to undergo proton transfer, and the production of intermediate II is suppressed, thereby suppressing the progress of the reaction. Under alkaline conditions, nitrone 2 is difficult to bind with a proton, inhibiting the formation of intermediate II, so that nitrone exists mainly in the form of 1. Therefore, the central N atom has a small positive charge density, an insufficient electron transfer tendency, and OH - Will surround N + Peripheral, strong solvation, weakening of N + The electron deficiency property of (3) reduces the attack of P negative ions on carbon-nitrogen double bonds, and inhibits the formation of the product 3. Thus, the reaction of the present invention is a nucleophilic addition reaction mechanism.
Example 1 synthesis of (((hydroxy) benzylamino) (phenyl) methyl) diphenylphosphine oxide compound (compound 1).
Compound 1 has the structural formula:
the first synthesis process comprises: adding N-benzyl-alpha-phenyl nitrone (0.001 mol), phosphorus diphenoxylate (0.0015 mol) and N-hexane (5 ml) into a round-bottom flask with the volume of 10ml in sequence, putting a magnetic stirrer, stirring at 500 revolutions per minute on the magnetic stirrer, reacting at the temperature of 60 ℃ for 2 hours, monitoring the reaction by TLC, and distilling the mixed solution under reduced pressure to remove the solvent when no nitrone compound remains to obtain an initial product. The crude product was then purified by recrystallization (solvent: n-hexane/ethyl acetate, 80). The yield thereof was found to be 93%.
The second method comprises the following synthetic processes: adding N-benzyl-alpha-phenyl nitrone (0.001 mol), phosphorus diphenoxylate (0.0015 mol) and water (10 ml) into a round bottom flask with the volume of 25ml in sequence, putting a magnetic stirrer, placing the flask on the magnetic stirrer, stirring every minute at 500 revolutions per minute, reacting at the temperature of 90 ℃ for 4 hours, monitoring the reaction by TLC, extracting the reaction solution with 50ml of multiplied by 3 ethyl acetate for three times when no nitrone compound is left, separating and combining organic layers, drying the organic phase with anhydrous sodium sulfate, filtering, distilling the filtrate under reduced pressure to remove the solvent to obtain the initial product. The crude product was then purified by recrystallization (solvent: n-hexane/ethyl acetate, 80). The yield thereof was found to be 93%.
The third synthesis process comprises: adding N-benzyl-alpha-phenyl nitrone (0.001 mol) and phosphorus diphenoxylate (0.002 mol) into a round-bottom flask with the volume of 10ml in sequence, reacting for 2 hours at the temperature of 65 ℃, monitoring the reaction by TLC, and distilling the mixed solution under reduced pressure to remove the solvent when no nitrone compound remains to obtain an initial product. The crude product was then purified by recrystallization (solvent: n-hexane/ethyl acetate, 80). The yield thereof was found to be 94%.
In the actual synthesis process, the synthesis method can be reasonably selected according to the aspects of reaction amount, cost, operation difficulty, whether the reaction is green, reaction yield and the like.
The structure of the compound 1 is detected by nuclear magnetic resonance, and the results are as follows:
1 H NMR(400MHz,CDCl 3 )δ7.86(t,J=9.2Hz,2H),7.50(ddt,J=25.1,19.5,8.5Hz,7H),7.38–6.98(m,11H),6.72(s,1H),4.64(d,J=7.2Hz,1H),4.10(d,J=13.1Hz,1H),3.64(d,J=13.2Hz,1H). 13 C NMR(101MHz,CDCl 3 )δ136.59,131.43,131.32,131.23,130.99,130.91,129.10,128.21,128.09,128.04,127.88,127.77,127.16,77.16,76.84,76.53,61.20.
EXAMPLE 2 Synthesis of (((hydroxy) benzylamino) (2-naphthyl) methyl) diphenylphosphine oxide Compound (Compound 2)
the synthesis process comprises the following steps: adding N-benzyl-alpha- (2-naphthyl) nitrone (0.001 mol), phosphorus diphenoxylate (0.0015 mol) and N-hexane (5 ml) into a round-bottom flask with the volume of 10ml in sequence, adding a magnetic stirrer, stirring at 500 revolutions per minute on the magnetic stirrer, reacting for 4 hours at the temperature of 60 ℃, monitoring the reaction by TLC, and distilling the mixed solution under reduced pressure to remove the solvent when no nitrone compound remains to obtain a primary product. The crude product was then purified by recrystallization (solvent: n-hexane/ethyl acetate, 80). The yield thereof was found to be 92%.
The structure of the compound 2 is detected by nuclear magnetic resonance, and the results are as follows:
1 H NMR(400MHz,CDCl 3 )δ7.93–7.85(m,3H),7.80–7.76(m,2H),7.74–7.67(m,2H),7.63(dd,J=8.5,1.6Hz,1H),7.60–7.54(m,2H),7.52–7.43(m,8H),7.25–7.23(m,2H),7.12(dt,J=7.3,2.4Hz,3H),4.80(d,J=7.4Hz,1H),4.09(d,J=13.2Hz,1H),3.63(d,J=13.2Hz,1H). 13 C NMR(101MHz,CDCl 3 )δ136.92,133.10,132.96,132.70,132.68,131.77,131.75,131.67,131.60,131.58,131.38,131.31,131.27,131.19,130.87,130.76,129.41,129.34,129.12,129.08,128.95,128.75,128.55,128.43,128.36,128.25,128.22,128.10,127.99,127.70,127.66,127.60,127.49,127.46,126.58,126.37,126.08,125.99,77.48,77.16,76.84,61.56,61.45.
example 3 synthesis of (((hydroxy) benzylamino) (cyclohexyl) methyl) diphenylphosphine oxide (compound 3).
Compound 3 has the structural formula:
the synthesis process comprises the following steps: adding N-benzyl-alpha-cyclohexyl nitrone (0.001 mol), diphenyl oxide phosphorus (0.0015 mol) and water (10 ml) into a round bottom flask with the volume of 25ml in sequence, putting a magnetic stirrer, placing the flask on the magnetic stirrer, stirring every minute at 500 revolutions per minute, reacting at the temperature of 90 ℃ for 3 hours, monitoring the reaction by TLC, extracting the reaction solution with 50ml of multiplied by 3 ethyl acetate for three times when no nitrone compound is left, separating and combining organic layers, drying the organic layer with anhydrous sodium sulfate, filtering, distilling the filtrate under reduced pressure to remove the solvent to obtain the initial product. The crude product was then purified by recrystallization (solvent: n-hexane/ethyl acetate, 80). The yield thereof was found to be 95%.
The structure of the compound 3 is detected by nuclear magnetic resonance, and the results are as follows:
1 H NMR(400MHz,CDCl 3 )δ7.68(tdd,J=8.4,4.6,1.5Hz,1H),7.62–7.56(m,3H),7.46(td,J=7.2,1.6Hz,2H),7.41–7.35(m,5H),7.06(dd,J=5.1,2.1Hz,1H),6.35(d,J=7.4Hz,1H),4.73(s,2H),2.86(tdt,J=11.1,7.4,3.7Hz,1H),1.77–1.69(m,2H),1.58–1.53(m,2H),1.27–1.16(m,2H),1.15–1.08(m,1H),1.01(qd,J=11.7,3.4Hz,3H). 13 C NMR(101MHz,CDCl 3 )δ143.37,137.66,133.26,132.67,132.64,131.97,131.73,131.31,131.21,131.13,131.04,130.96,130.83,130.72,129.10,129.04,128.95,128.92,128.83,128.64,128.57,128.52,128.46,128.43,128.21,127.24,77.48,77.16,76.84,69.38,35.09,28.83,26.76,26.13,25.99,25.28.
EXAMPLE 4 Synthesis of (((hydroxy) benzylamino) (2-furan) methyl) diphenylphosphine oxide Compound (Compound 4)
Compound 4 has the structural formula:
adding N-benzyl-alpha- (2-furan) nitrone (0.001 mol), phosphorus diphenoxylate (0.0015 mol) and N-hexane (5 ml) into a round-bottom flask with the volume of 10ml in sequence, adding a magnetic stirrer, placing the mixture on the magnetic stirrer for 500 revolutions per minute, stirring at the temperature (60 ℃) for 3 hours, monitoring the reaction by TLC, and when no nitrone compound remains, distilling the mixed solution under reduced pressure to remove the solvent to obtain an initial product. The crude product was then purified by recrystallization (solvent: petroleum ether/ethyl acetate, 70). The yield thereof was found to be 91%.
The structure of the compound 4 is detected by nuclear magnetic resonance, and the results are as follows:
1 H NMR(400MHz,CDCl 3 )δ7.67–7.60(m,2H),7.50–7.30(m,7H),7.27–7.14(m,6H),7.10–7.01(m,2H),6.61(t,J=2.6Hz,1H),6.25(dd,J=3.3,1.9Hz,1H),4.73(d,J=11.1Hz,1H),4.07(d,J=12.6Hz,1H),3.58(d,J=12.7Hz,1H). 13 C NMR(101MHz,CDCl 3 )δ144.85,144.80,142.48,142.46,136.15,131.67,131.64,131.63,131.60,131.33,131.24,130.83,130.78,130.69,129.84,129.41,128.27,128.15,128.09,127.97,127.31,113.52,113.48,110.76,77.16,76.84,76.52,61.45.
EXAMPLE 5 Synthesis of (((hydroxy) benzylamino) (4-fluorophenyl) methyl) diphenylphosphine oxide Compound (Compound 5)
Compound 5 has the structural formula:
the synthesis process comprises the following steps: adding N-benzyl-alpha- (4-fluorophenyl) nitrone (0.001 mol), phosphorus diphenoxylate (0.0015 mol) and N-hexane (5 ml) into a round-bottom flask with the volume of 10ml in sequence, adding a magnetic stirrer, stirring at 500 revolutions per minute on the magnetic stirrer, reacting at the temperature of 60 ℃ for 3 hours, monitoring the reaction by TLC, and distilling the mixed solution under reduced pressure to remove the solvent when no nitrone compound remains to obtain an initial product. The crude product was then purified by recrystallization (solvent: petroleum ether/ethyl acetate, 80. The yield thereof was found to be 82%.
The structure of the compound 5 is detected by nuclear magnetic resonance, and the results are as follows:
1 H NMR(400MHz,CDCl 3 )δ7.86–7.78(m,2H),7.56(td,J=7.3,1.5Hz,1H),7.52–7.28(m,8H),7.27–7.19(m,5H),7.12–7.05(m,2H),6.93(t,J=8.6Hz,2H),6.72(s,1H),4.59(d,J=7.6Hz,1H),4.06(d,J=13.1Hz,1H),3.58(d,J=13.1Hz,1H). 13 C NMR(101MHz,CDCl 3 )δ136.35,133.25,133.18,131.51,131.34,131.29,131.21,130.89,130.80,129.07,128.25,128.13,128.09,128.01,127.89,127.26,114.96,114.75,77.16,76.84,76.52,61.17,61.05.
EXAMPLE 6 Synthesis of (((hydroxy) benzylamino) (4-chlorophenyl) methyl) diphenylphosphine oxide Compound (Compound 6)
Compound 6 has the structural formula:
adding N-benzyl-alpha- (4-chlorphenyl) nitrone (0.001 mol), phosphorus diphenoxy (0.0015 mol) and N-hexane (5 ml) into a round bottom flask with the volume of 10ml in sequence, adding a magnetic stirrer, placing the mixture on the magnetic stirrer for 500 revolutions per minute, stirring at the temperature (60 ℃) for 3 hours, monitoring the reaction by TLC, and distilling the mixed solution under reduced pressure to remove the solvent when no nitrone compound remains to obtain an initial product. The crude product was then purified by recrystallization (solvent: petroleum ether/ethyl acetate, 80). The yield thereof was found to be 84%.
The structure of the compound 6 is detected by nuclear magnetic resonance, and the results are as follows:
1 H NMR(400MHz,CDCl 3 )δ7.87–7.81(m,2H),7.59(td,J=7.3,1.5Hz,1H),7.53–7.41(m,6H),7.36(td,J=7.3,1.4Hz,1H),7.30–7.22(m,7H),7.13–7.04(m,2H),6.69(s,1H),4.61(d,J=7.6Hz,1H),4.08(d,J=13.1Hz,1H),3.60(d,J=13.1Hz,1H). 13 C NMR(101MHz,CDCl 3 )δ132.82,132.75,131.58,131.50,131.31,131.22,130.90,130.82,129.10,128.30,128.18,128.14,128.10,127.98,127.34,77.16,76.84,76.53,61.21,61.10.
EXAMPLE 7 Synthesis of (((hydroxy) benzylamino) (4-bromophenyl) methyl) diphenylphosphine oxide Compound (Compound 7)
Compound 7 has the structural formula:
adding N-benzyl-alpha- (4-bromophenyl) nitrone (0.001 mol), phosphorus diphenoxylate (0.0015 mol) and N-hexane (5 ml) into a round-bottom flask with the volume of 10ml in sequence, adding a magnetic stirrer, stirring at 500 revolutions per minute on the magnetic stirrer, reacting at the temperature of 60 ℃ for 3 hours, monitoring the reaction by TLC, and distilling the mixed solution under reduced pressure to remove the solvent when no nitrone compound remains to obtain an initial product. The crude product was then purified by recrystallization (solvent: petroleum ether/ethyl acetate, 80. The yield thereof was found to be 84%.
The structure of the compound 7 is detected by nuclear magnetic resonance, and the results are as follows:
1 H NMR(400MHz,CDCl 3 )δ7.85–7.78(m,2H),7.56(td,J=7.3,1.5Hz,1H),7.51–7.45(m,2H),7.44–7.31(m,7H),7.27–7.20(m,5H),7.11–7.03(m,2H),6.72(s,1H),4.58(d,J=7.6Hz,1H),4.05(d,J=13.1Hz,1H),3.58(d,J=13.1Hz,1H). 13 C NMR(101MHz,CDCl 3 )δ136.19,133.11,133.05,131.58,131.48,131.30,131.21,131.03,130.89,130.80,130.06,129.09,128.28,128.16,128.12,128.10,127.98,127.32,122.48,77.16,76.84,76.53,61.21,61.10.
EXAMPLE 8 Synthesis of (((hydroxy) benzylamino) (4- (trifluoromethyl) phenyl) methyl) diphenylphosphine oxide Compound (Compound 8)
Compound 8 has the structural formula:
adding N-benzyl-alpha- (4- (trifluoromethyl) phenyl) nitrone (0.001 mol), phosphorus diphenoxy (0.0015 mol) and N-hexane (5 ml) into a round-bottom flask with the volume of 10ml in sequence, adding a magnetic stirrer, stirring every minute at 500 revolutions per minute on the magnetic stirrer, reacting for 3 hours at the temperature of 60 ℃, monitoring the reaction by TLC, and distilling the mixed solution under reduced pressure to remove the solvent when no nitrone compound remains to obtain an initial product. The crude product was then purified by recrystallization (solvent: petroleum ether/ethyl acetate, 80. The yield thereof was found to be 85%.
The structure of the compound 8 is detected by nuclear magnetic resonance, and the results are as follows:
1 H NMR(400MHz,CDCl 3 )δ7.76(ddd,J=11.4,8.3,1.4Hz,2H),7.50(td,J=8.0,7.4,1.4Hz,3H),7.41(ddt,J=6.6,5.2,2.1Hz,4H),7.36–7.28(m,2H),7.24(td,J=7.4,1.5Hz,1H),7.19–7.10(m,5H),7.01(dd,J=7.4,2.2Hz,2H),6.71(s,1H),4.58(d,J=7.3Hz,1H),3.99(d,J=13.1Hz,1H),3.50(d,J=13.2Hz,1H). 13 C NMR(101MHz,CDCl 3 )δ136.50,135.78,132.72,132.10,132.04,131.96,131.93,131.86,131.83,131.72,131.64,131.56,131.27,131.16,131.08,130.54,130.29,130.22,129.40,128.63,128.51,128.46,128.41,128.30,127.68,125.46,125.00,124.96,124.92,122.75,77.48,77.36,77.16,76.84,69.11,68.23,61.76,61.65.
EXAMPLE 9 Synthesis of (((hydroxy) benzylamino) (3-chlorophenyl) methyl) diphenylphosphine oxide Compound (Compound 9)
Compound 9 has the structural formula:
adding N-benzyl-alpha- (3-chlorphenyl) nitrone (0.001 mol), phosphorus diphenoxylate (0.0015 mol) and N-hexane (5 ml) into a round-bottom flask with the volume of 10ml in sequence, adding a magnetic stirrer, stirring at 500 revolutions per minute on the magnetic stirrer, reacting at the temperature of 60 ℃ for 3 hours, monitoring the reaction by TLC, and distilling the mixed solution under reduced pressure to remove the solvent when no nitrone compound remains to obtain an initial product. The crude product was then purified by recrystallization (solvent: petroleum ether/ethyl acetate, 80. The yield thereof was found to be 84%.
The structure of the compound 9 is detected by nuclear magnetic resonance, and the results are as follows:
1 H NMR(400MHz,CDCl 3 )δ7.90–7.83(m,2H),7.60(td,J=7.4,1.7Hz,1H),7.54–7.42(m,6H),7.36(td,J=7.4,1.6Hz,1H),7.31–7.23(m,6H),7.22–7.13(m,3H),7.12–6.74(m,1H),4.62(d,J=7.1Hz,1H),4.13(d,J=13.2Hz,1H),3.64(d,J=13.2Hz,1H). 13 C NMR(101MHz,CDCl 3 )δ136.31,133.62,133.37,132.51,131.49,131.47,131.40,131.37,131.27,131.21,131.18,131.03,130.88,130.80,130.05,129.61,129.55,129.09,129.01,128.23,128.18,128.17,128.11,128.05,127.98,127.86,127.22,77.16,76.84,76.52,61.39,61.28.
EXAMPLE 10 Synthesis of (((hydroxy) benzylamino) (3-fluorophenyl) methyl) diphenylphosphine oxide Compound (Compound 10)
Compound 10 has the structural formula:
adding N-benzyl-alpha- (3-fluorophenyl) nitrone (0.001 mol), phosphorus diphenoxylate (0.0015 mol) and N-hexane (5 ml) into a round-bottom flask with the volume of 10ml in sequence, adding a magnetic stirrer, stirring at 500 revolutions per minute on the magnetic stirrer, reacting at the temperature of 60 ℃ for 3 hours, monitoring the reaction by TLC, and distilling the mixed solution under reduced pressure to remove the solvent when no nitrone compound remains to obtain an initial product. Then the primary product is purified by a pulping method (solvent: petroleum ether or normal hexane) to obtain a pure product. The yield thereof was found to be 87%.
The structure of the compound 10 is detected by nuclear magnetic resonance, and the results are as follows:
1 H NMR(400MHz,CDCl 3 )δ7.90–7.82(m,2H),7.62–7.58(m,1H),7.57–7.43(m,5H),7.36(td,J=7.3,1.5Hz,1H),7.27(tq,J=10.8,3.7Hz,8H),7.13(dd,J=7.2,2.4Hz,2H),7.01–6.94(m,1H),4.63(d,J=7.4Hz,1H),4.12(d,J=13.1Hz,1H),3.65(d,J=13.1Hz,1H). 13 C NMR(101MHz,CDCl 3 )δ136.63,133.93,132.88,132.72,131.88,131.85,131.74,131.72,131.62,131.53,131.38,131.23,131.15,130.89,130.78,130.40,129.56,129.48,129.42,129.09,128.97,128.59,128.47,128.42,128.33,128.22,127.60,118.84,118.77,118.56,115.53,115.31,77.48,77.16,76.84,61.66.
EXAMPLE 11 Synthesis of (((hydroxy) benzylamino) (2-bromophenyl) methyl) diphenylphosphine oxide (Compound 11) Compound 11:
adding N-benzyl-alpha- (2-bromophenyl) nitrone (0.001 mol), phosphorus diphenoxylate (0.0015 mol) and N-hexane (5 ml) into a round-bottom flask with the volume of 10ml in sequence, adding a magnetic stirrer, stirring at 500 revolutions per minute on the magnetic stirrer, reacting at the temperature of 60 ℃ for 3 hours, monitoring the reaction by TLC, and distilling the mixed solution under reduced pressure to remove the solvent when no nitrone compound remains to obtain an initial product. Then the primary product is purified by a pulping method (solvent: petroleum ether or normal hexane) to obtain a pure product. The yield thereof was found to be 85%.
The structure of the compound 11 is detected by nuclear magnetic resonance, and the results are as follows:
1 H NMR(400MHz,CDCl 3 )δ8.33(d,J=7.9Hz,1H),8.05(ddd,J=11.3,8.1,1.6Hz,2H),7.66–7.51(m,6H),7.45–7.42(m,1H),7.36–7.31(m,2H),7.26(td,J=5.1,4.7,2.2Hz,6H),7.11(t,J=7.7Hz,1H),6.71(s,1H),5.57(d,J=6.0Hz,1H),3.97–3.87(m,2H). 13 C NMR(101MHz,CDCl 3 )δ137.43,133.68,133.64,133.41,132.38,132.30,131.72,131.69,131.53,131.50,131.40,131.38,131.29,131.14,131.05,129.81,129.79,129.02,128.60,128.48,128.05,127.98,127.86,127.50,127.48,127.15,126.25,126.16,77.43,77.11,76.79,62.20,62.08.
EXAMPLE 12 Synthesis of (((hydroxy) benzylamino) (4-nitrophenyl) methyl) diphenylphosphine oxide Compound (Compound 12)
Compound 12 has the structural formula:
adding N-benzyl-alpha- (4-nitrophenyl) nitrone (0.001 mol), phosphorus diphenoxy (0.0015 mol) and N-hexane (5 ml) into a round-bottom flask with the volume of 10ml in sequence, adding a magnetic stirrer, stirring every minute at 500 revolutions per minute on the magnetic stirrer, reacting for 4 hours at the temperature of 60 ℃, monitoring the reaction by TLC, and distilling the mixed solution under reduced pressure to remove the solvent when no nitrone compound remains to obtain an initial product. Then purifying the primary product by a pulping method (solvent: petroleum ether or normal hexane) to obtain a pure product. The yield thereof was found to be 83%.
The structure of the compound 12 is detected by nuclear magnetic resonance, and the results are as follows:
1 H NMR(400MHz,CDCl 3 )δ8.07(d,J=8.4Hz,2H),7.87–7.81(m,2H),7.64(d,J=8.3Hz,2H),7.58(dd,J=7.5,1.6Hz,1H),7.49(td,J=7.6,3.1Hz,2H),7.44–7.36(m,3H),7.33(dd,J=7.5,1.6Hz,1H),7.28–7.22(m,5H),7.12–7.07(m,2H),4.72(d,J=7.0Hz,1H),4.07(d,J=13.1Hz,1H),3.59(d,J=13.1Hz,1H). 13 C NMR(101MHz,CDCl 3 )δ147.60,139.45,136.12,132.52,132.46,131.99,131.97,131.94,131.91,131.50,131.41,131.00,130.92,129.33,128.59,128.47,128.44,128.41,128.32,127.71,122.96,77.40,77.08,76.76,68.82,67.95,61.97,61.86.
EXAMPLE 13 Synthesis of (((hydroxy) benzylamino) (2-chlorophenyl) methyl) diphenylphosphine oxide Compound (Compound 13)
Compound 13 has the structural formula:
adding N-benzyl-alpha- (2-chlorphenyl) nitrone (0.001 mol), phosphorus diphenoxylate (0.0015 mol) and N-hexane (5 ml) into a round-bottom flask with the volume of 10ml in sequence, adding a magnetic stirrer, stirring at 500 revolutions per minute on the magnetic stirrer, reacting at the temperature of 60 ℃ for 3 hours, monitoring the reaction by TLC, and distilling the mixed solution under reduced pressure to remove the solvent when no nitrone compound remains to obtain an initial product. Then the primary product is purified by a pulping method (solvent: petroleum ether or normal hexane) to obtain a pure product. The yield thereof was found to be 84%.
The structure of the compound 13 is detected by nuclear magnetic resonance, and the results are as follows:
1 H NMR(400MHz,CDCl 3 )δ8.27(d,J=7.8Hz,1H),7.97(ddd,J=11.3,8.2,1.5Hz,2H),7.59(dd,J=7.2,1.6Hz,1H),7.57–7.51(m,3H),7.50–7.48(m,1H),7.35–7.30(m,1H),7.29–7.20(m,7H),7.17(dt,J=8.6,5.1Hz,3H),6.59(s,1H),5.49(d,J=6.5Hz,1H),3.96–3.76(m,2H). 13 C NMR(101MHz,CDCl 3 )δ137.32,133.71,133.68,133.40,132.68,132.40,131.84,131.81,131.65,131.63,131.48,131.39,131.10,131.01,130.89,130.77,130.48,130.38,129.63,129.61,129.38,129.13,129.07,128.96,128.67,128.55,128.14,128.12,128.00,127.28,126.95,126.93,77.48,77.16,76.84,62.28,62.16.
EXAMPLE 14 Synthesis of (((hydroxy) benzylamino) (2,6-dichlorophenyl) methyl) diphenylphosphine oxide Compound (Compound 14)
Compound 14 is of the formula:
adding N-benzyl-alpha- (2,6-dichlorophenyl) nitrone (0.001 mol), phosphorus diphenoxy (0.0015 mol) and N-hexane (5 ml) into a round-bottom flask with the volume of 10ml in sequence, adding a magnetic stirrer, stirring at 500 revolutions per minute on the magnetic stirrer, reacting for 3 hours at the temperature of 60 ℃, monitoring the reaction by TLC, and distilling the mixed solution under reduced pressure to remove the solvent to obtain an initial product when no nitrone compound is left. Then the primary product is purified by a pulping method (solvent: petroleum ether or normal hexane) to obtain a pure product. The yield thereof was found to be 81%.
The structure of compound 14 was examined by nmr and the results were as follows:
1 H NMR(400MHz,CDCl 3 )δ8.17–8.07(m,2H),7.72–7.64(m,2H),7.57(dt,J=6.1,2.6Hz,3H),7.46–7.40(m,2H),7.36–7.22(m,7H),7.13(dd,J=8.0,1.3Hz,1H),7.03(td,J=8.0,1.5Hz,1H),6.70(s,1H),6.09(d,J=4.2Hz,1H),3.92–3.76(m,2H). 13 C NMR(101MHz,CDCl 3 )δ137.34,136.82,136.78,136.19,136.12,135.60,134.59,131.51,131.28,131.26,131.14,131.11,130.99,130.97,130.90,130.88,130.14,130.12,129.43,129.40,128.86,128.41,128.30,127.83,127.77,127.30,127.18,126.89,77.16,76.84,76.53,71.22,70.38,62.43,62.32.
EXAMPLE 15 Synthesis of (((hydroxy) benzylamino) (4-methylphenyl) methyl) diphenylphosphine oxide Compound (Compound 15)
Compound 15 has the structural formula:
sequentially adding N-benzyl-alpha- (4-methylphenyl) nitrone (0.001 mol) and phosphorus diphenoxylate (0.002 mol) into a round-bottom flask with the volume of 10ml, enabling the reactants to be in a molten state at the temperature of 65 ℃, reacting for 2 hours, monitoring the reaction by TLC, and distilling the mixed solution under reduced pressure to remove the solvent when no nitrone compound remains to obtain an initial product. The crude product was then purified by recrystallization (solvent: n-hexane/ethyl acetate, 80). The yield thereof was found to be 91%.
The structure of compound 15 was examined by nmr and the results are as follows:
1 H NMR(400MHz,CDCl 3 )δ7.73(ddd,J=11.2,8.3,1.4Hz,2H),7.47(td,J=6.5,5.8,1.5Hz,1H),7.37(dddd,J=12.6,11.0,7.4,2.3Hz,4H),7.24(ddd,J=11.9,7.6,1.4Hz,3H),7.17–7.10(m,5H),7.01(dd,J=7.3,2.3Hz,2H),6.96(d,J=7.8Hz,2H),6.58(s,1H),4.48(d,J=7.4Hz,1H),3.97(d,J=13.2Hz,1H),3.50(d,J=13.1Hz,1H),2.20(s,3H). 13 C NMR(101MHz,CDCl 3 )δ138.16,137.00,133.28,131.73,131.67,131.63,131.54,131.50,131.32,131.24,129.41,128.93,128.49,128.37,128.33,128.21,128.10,127.41,77.48,77.16,76.84,61.37,61.26,21.32.
EXAMPLE 16 Synthesis of (((hydroxy) benzylamino) (3-methylphenyl) methyl) diphenylphosphine oxide Compound (Compound 16)
Compound 16 has the structural formula:
the synthesis process comprises the following steps: sequentially adding N-benzyl-alpha- (3-methylphenyl) nitrone (0.001 mol) and phosphorus diphenoxylate (0.002 mol) into a round-bottom flask with the volume of 10ml, enabling the reactants to be in a molten state at the temperature of 65 ℃, reacting for 2 hours, monitoring the reaction by TLC, and distilling the mixed solution under reduced pressure to remove the solvent when no nitrone compound remains to obtain an initial product. The crude product was then purified by recrystallization (solvent: n-hexane/ethyl acetate, 80). The yield thereof was found to be 90%.
The structure of the compound 16 is detected by nuclear magnetic resonance, and the results are as follows:
1 H NMR(400MHz,CDCl 3 )δ7.85(ddd,J=11.2,8.3,1.4Hz,2H),7.78–7.70(m,1H),7.62–7.57(m,1H),7.57–7.53(m,1H),7.53–7.49(m,2H),7.47(d,J=1.3Hz,1H),7.46–7.42(m,2H),7.36–7.31(m,1H),7.28–7.23(m,6H),7.16–7.14(m,2H),7.07(d,J=7.6Hz,1H),4.61(d,J=6.9Hz,1H),4.10(d,J=13.2Hz,1H),3.65(d,J=13.2Hz,1H),2.28(s,3H). 13 C NMR(101MHz,CDCl 3 )δ137.76,137.01,132.72,132.69,132.41,132.35,132.29,131.69,131.66,131.64,131.55,131.51,131.49,131.36,131.33,131.28,130.89,130.78,129.42,129.36,129.15,129.13,129.09,128.97,128.81,128.75,128.50,128.44,128.38,128.32,128.12,128.03,128.01,127.43,77.48,77.16,76.84,61.55,61.44,21.50.
EXAMPLE 17 Synthesis of (((hydroxy) benzylamino) (3,4-dimethylphenyl) methyl) diphenylphosphine oxide (Compound 17)
Compound 17 has the structural formula:
sequentially adding N-benzyl-alpha- (3,4-dimethylphenyl) nitrone (0.001 mol), phosphorus diphenoxy (0.0015 mol) and N-hexane (5 ml) into a round-bottom flask with the volume of 10ml, putting a magnetic stirrer, stirring at 500 revolutions per minute on the magnetic stirrer, reacting for 3 hours at the temperature of 60 ℃, monitoring the reaction by TLC, and distilling the mixed solution under reduced pressure to remove the solvent to obtain a primary product when no nitrone compound is left. The crude product was then purified by recrystallization (solvent: n-hexane/ethyl acetate, 60. The yield thereof was found to be 89%.
The structure of compound 17 was examined by nmr and the results were as follows:
1 H NMR(400MHz,CDCl 3 )δ7.88–7.82(m,2H),7.75(ddd,J=13.8,8.1,1.4Hz,1H),7.61–7.58(m,1H),7.58–7.55(m,1H),7.51(dq,J=6.9,4.0,3.0Hz,4H),7.44(d,J=6.9Hz,1H),7.38–7.33(m,1H),7.26(dd,J=5.1,2.0Hz,4H),7.20(d,J=8.0Hz,1H),7.15–7.13(m,1H),7.04(d,J=7.7Hz,1H),6.66(s,1H),4.60(d,J=7.5Hz,1H),4.11(d,J=13.2Hz,1H),3.64(d,J=13.2Hz,1H),2.22(d,J=6.8Hz,6H). 13 C NMR(101MHz,CDCl 3 )δ137.02,136.71,136.69,136.22,132.85,132.79,132.62,132.59,131.57,131.54,131.51,131.49,131.39,131.36,131.29,131.20,130.79,130.68,129.72,129.67,129.32,129.29,129.23,129.19,129.13,128.99,128.95,128.90,128.87,128.37,128.33,128.25,128.20,128.05,127.94,127.27,126.49,71.00,61.26,61.15,19.77,19.54.
EXAMPLE 18 Synthesis of (((hydroxy) benzylamino) (4-methoxyphenyl) methyl) diphenylphosphine oxide Compound (Compound 18)
Compound 18 has the structural formula:
adding N-benzyl-alpha- (4-methoxyphenyl) nitrone (0.001 mol), phosphorus diphenoxylate (0.0015 mol) and water (10 ml) into a round bottom flask with the volume of 25ml in sequence, putting a magnetic stirrer, placing the flask on the magnetic stirrer for 500 revolutions per minute, stirring, reacting at the temperature of 90 ℃ for 4 hours, monitoring the reaction by TLC, extracting the reaction solution with 50ml of multiplied by 3 ethyl acetate for three times when no nitrone compound is left, separating and combining organic layers, drying the organic layer with anhydrous sodium sulfate, filtering, distilling the filtrate under reduced pressure to remove the solvent to obtain the initial product. The crude product was then purified by recrystallization (solvent: n-hexane/ethyl acetate, 80). The yield thereof was found to be 93%.
The structure of compound 18 was examined by nmr and the results are as follows:
1 H NMR(400MHz,CDCl 3 )δ7.79(ddd,J=11.2,6.9,1.9Hz,2H),7.53–7.49(m,1H),7.47–7.34(m,6H),7.28(d,J=1.7Hz,1H),7.24–7.16(m,5H),7.10–7.01(m,2H),6.79–6.50(m,3H),4.53(t,J=7.5Hz,1H),4.03(dd,J=13.1,3.9Hz,1H),3.73(d,J=4.3Hz,3H),3.56(dd,J=13.1,2.6Hz,1H). 13 C NMR(101MHz,CDCl 3 )δ159.62,137.05,133.11,131.67,131.56,131.31,131.23,129.40,128.51,128.40,128.36,128.27,128.15,127.44,113.63,77.48,77.16,76.84,61.33,61.21,55.29,29.84.
EXAMPLE 19 Synthesis of (((hydroxy) benzylamino) (3-methoxyphenyl) methyl) diphenylphosphine oxide Compound (Compound 19)
Compound 19 is of the formula:
the synthesis process comprises the following steps: adding N-benzyl-alpha- (3-methoxyphenyl) nitrone (0.001 mol), phosphorus diphenoxylate (0.0015 mol) and water (10 ml) into a round bottom flask with the volume of 25ml in sequence, putting a magnetic stirrer, placing the flask on the magnetic stirrer for 500 revolutions per minute, stirring, reacting at the temperature of 90 ℃ for 4 hours, monitoring the reaction by TLC, extracting the reaction solution with 50ml of multiplied by 3 ethyl acetate for three times when no nitrone compound is left, separating and combining organic layers, drying the organic layer with anhydrous sodium sulfate, filtering, distilling the filtrate under reduced pressure to remove the solvent to obtain the initial product. The crude product was then purified by recrystallization (solvent: n-hexane/ethyl acetate, 80). The yield thereof was found to be 92%.
The structure of compound 19 was examined by nmr and the results were as follows:
1 H NMR(400MHz,CDCl 3 )δ7.84–7.77(m,2H),7.69(ddd,J=13.7,8.2,1.4Hz,2H),7.54(dt,J=3.8,1.7Hz,1H),7.51(dd,J=4.1,2.2Hz,1H),7.48–7.45(m,3H),7.41(dt,J=3.7,1.2Hz,1H),7.39(d,J=1.6Hz,1H),7.31–7.28(m,1H),7.21(dd,J=5.2,2.1Hz,3H),7.12–7.09(m,2H),7.05–7.00(m,1H),6.98–6.94(m,1H),6.79–6.74(m,1H),4.59(d,J=6.8Hz,1H),4.07(d,J=13.2Hz,1H),3.81(s,1H),3.70(s,3H). 13 C NMR(101MHz,CDCl 3 )δ159.32,132.72,132.69,131.76,131.62,131.53,131.35,131.26,130.89,130.78,129.51,129.38,129.36,129.12,129.09,128.97,128.54,128.42,128.34,128.20,128.09,127.52,121.83,114.60,112.34,55.35.
EXAMPLE 20 Synthesis of (((hydroxy) benzylamino) (2-methoxyphenyl) methyl) diphenylphosphine oxide Compound (Compound 20)
Compound 20 is of the formula:
adding N-benzyl-alpha- (2-methoxyphenyl) nitrone (0.001 mol), phosphorus diphenoxy (0.0015 mol) and N-hexane (5 ml) into a round-bottom flask with the volume of 10ml in sequence, adding a magnetic stirrer, stirring every minute at 500 revolutions per minute on the magnetic stirrer, reacting for 3 hours at the temperature of 60 ℃, monitoring the reaction by TLC, and distilling the mixed solution under reduced pressure to remove the solvent when no nitrone compound remains to obtain an initial product. The crude product was then purified by recrystallization (solvent: n-hexane/ethyl acetate, 80). The yield thereof was found to be 92%.
The structure of the compound 20 is detected by nuclear magnetic resonance, and the results are as follows:
1 H NMR(400MHz,CDCl 3 )δ8.10(d,J=7.7Hz,1H),7.93–7.86(m,2H),7.57–7.39(m,5H),7.30–7.10(m,9H),6.92(td,J=7.5,1.1Hz,1H),6.65(dt,J=8.3,1.1Hz,1H),6.57(s,1H),5.42(d,J=6.8Hz,1H),3.95(d,J=13.5Hz,1H),3.69(d,J=13.4Hz,1H),3.60(s,3H). 13 C NMR(101MHz,CDCl 3 )δ156.80,156.74,137.20,133.51,132.52,131.62,131.22,131.20,131.17,131.13,130.97,130.94,130.72,130.63,129.12,129.10,128.89,128.12,128.00,127.66,127.45,127.34,126.81,120.36,120.34,120.18,109.37,77.16,76.84,76.52,61.78,61.66,54.78.
EXAMPLE 21 Synthesis of (((hydroxy) benzylamino) (3,5-dimethoxyphenyl) methyl) diphenylphosphine oxide Compound (Compound 21)
Compound 21 is of the formula:
adding N-benzyl-alpha- (3,5-dimethoxyphenyl) nitrone (0.001 mol), phosphorus diphenoxy (0.0015 mol) and N-hexane (5 ml) into a round-bottom flask with the volume of 10ml in sequence, putting a magnetic stirrer, stirring at 500 revolutions per minute on the magnetic stirrer, reacting for 3 hours at the temperature (60 ℃), monitoring the reaction by TLC, and distilling the mixed solution under reduced pressure to remove the solvent when no nitrone compound remains to obtain an initial product. The crude product was then purified by recrystallization (solvent: n-hexane/ethyl acetate, 80). The yield thereof was found to be 90%.
The structure of the compound 21 is detected by nuclear magnetic resonance, and the results are as follows:
1 H NMR(400MHz,CDCl 3 )δ7.86–7.77(m,2H),7.60–7.39(m,7H),7.37–7.31(m,1H),7.23(dt,J=4.9,2.4Hz,4H),7.13(dd,J=6.6,2.9Hz,2H),6.63–6.56(m,2H),6.33(d,J=1.2Hz,1H),4.55(d,J=6.7Hz,1H),4.09(d,J=13.2Hz,1H),3.79(s,1H),3.68(s,6H). 13 C NMR(101MHz,CDCl 3 )δ160.36,133.63,133.11,132.68,132.12,131.77,131.74,131.64,131.60,131.55,131.38,131.29,130.89,130.78,130.73,129.47,129.38,129.13,129.09,128.96,128.54,128.42,128.34,128.21,128.09,127.50,109.62,109.56,100.94,77.48,77.16,76.84,55.59,55.47.
EXAMPLE 22 Synthesis of (((hydroxy) benzylamino) (4- (acetoxy) phenyl) methyl) diphenylphosphine oxide Compound (Compound 22)
Compound 22 has the structural formula:
adding N-benzyl-alpha- (4- (acetoxyl) phenyl) nitrone (0.001 mol), phosphorus diphenoxy (0.0015 mol) and N-hexane (5 ml) into a round-bottom flask with the volume of 10ml in sequence, adding a magnetic stirrer, placing the flask on the magnetic stirrer for 500 revolutions per minute, stirring at the temperature of 60 ℃ for 3 hours, monitoring the reaction by TLC, and when no nitrone compound remains, distilling the mixed solution under reduced pressure to remove the solvent to obtain an initial product. Then the primary product is purified by a pulping method (solvent: petroleum ether or normal hexane) to obtain a pure product. The yield thereof was found to be 84%.
The structure of compound 22 was examined by nmr and the results are as follows:
1 H NMR(400MHz,CDCl 3 )δ7.85–7.78(m,2H),7.73–7.66(m,1H),7.54(dd,J=7.6,1.6Hz,1H),7.48–7.43(m,4H),7.42–7.35(m,3H),7.30(dd,J=7.5,1.6Hz,1H),7.24–7.20(m,4H),7.10(dt,J=7.4,3.5Hz,2H),6.97(d,J=8.3Hz,2H),4.62(d,J=7.2Hz,1H),4.07(d,J=13.2Hz,1H),3.61(d,J=13.2Hz,1H),2.26(s,3H). 13 C NMR(101MHz,CDCl 3 )δ169.11,150.76,136.79,132.71,132.68,132.65,131.78,131.75,131.65,131.62,131.53,131.25,131.16,130.87,130.75,130.03,129.40,129.31,129.10,129.07,128.95,128.53,128.42,128.36,128.30,128.19,127.50,121.74,121.25,77.48,77.16,76.84,21.29.
EXAMPLE 23 Synthesis of (((hydroxy) benzylamino) (4- (dimethylamino) phenyl) methyl) diphenylphosphine oxide Compound (Compound 23)
Compound 23 is of the formula:
adding N-benzyl-alpha- (4- (dimethylamino) phenyl) nitrone (0.001 mol), phosphorus diphenoxy (0.0015 mol) and N-hexane (5 ml) into a round-bottom flask with the volume of 10ml in sequence, adding a magnetic stirrer, stirring every minute at 500 revolutions per minute on the magnetic stirrer, reacting for 3 hours at the temperature of 60 ℃, monitoring the reaction by TLC, and when no nitrone compound remains, distilling the mixed solution under reduced pressure to remove the solvent to obtain an initial product. The crude product was then purified by recrystallization (solvent: n-hexane/ethyl acetate, 80). The yield thereof was found to be 88%.
The structure of the compound 23 is detected by nuclear magnetic resonance, and the results are as follows:
1 H NMR(400MHz,CDCl 3 )δ9.44(s,3H),7.57–7.51(m,5H),7.30(td,J=7.4,1.4Hz,3H),7.26(s,2H),7.19(dp,J=7.3,2.9Hz,7H),7.12(d,J=6.0Hz,5H),3.43(s,2H),1.30–1.22(m,2H). 13 C NMR(101MHz,CDCl 3 )δ134.00,131.30,131.21,130.26,128.66,128.18,128.11,127.98,77.48,77.16,76.84,42.74.
EXAMPLE 24 Synthesis of (((hydroxy) benzylamino) (4-isopropylphenyl) methyl) diphenylphosphine oxide Compound (Compound 24)
Compound 24 is of the formula:
adding N-benzyl-alpha- (4-isopropylphenyl) nitrone (0.001 mol), phosphorus diphenoxy (0.0015 mol) and N-hexane (5 ml) into a round-bottom flask with the volume of 10ml in sequence, adding a magnetic stirrer, stirring at 500 revolutions per minute on the magnetic stirrer, reacting at the temperature of 60 ℃ for 3 hours, monitoring the reaction by TLC, and distilling the mixed solution under reduced pressure to remove the solvent when no nitrone compound remains to obtain an initial product. The crude product was then purified by recrystallization (solvent: n-hexane/ethyl acetate, 80). The yield thereof was found to be 95%.
The structure of the compound 24 is detected by nuclear magnetic resonance, and the results are as follows:
1 H NMR(400MHz,CDCl 3 )δ7.82(ddd,J=11.2,8.3,1.4Hz,2H),7.57–7.51(m,1H),7.46(ddd,J=8.5,6.6,3.1Hz,2H),7.42–7.34(m,4H),7.31–7.26(m,1H),7.24–7.15(m,5H),7.14–7.05(m,4H),6.66(s,1H),4.59(d,J=7.0Hz,1H),4.08(d,J=13.1Hz,1H),3.62(d,J=13.2Hz,1H),2.83(p,J=6.9Hz,1H),1.22–1.14(m,6H). 13 C NMR(101MHz,CDCl 3 )δ149.00,148.98,137.08,133.33,132.34,131.86,131.65,131.61,131.58,131.56,131.37,131.34,131.32,131.24,130.88,129.38,128.62,128.44,128.33,128.28,128.07,127.96,127.36,126.23,77.48,77.16,76.84,61.47,61.35,33.85,23.99,23.95.
EXAMPLE 25 Synthesis of (((hydroxy) benzylamino) (1,1' -biphenyl) methyl) diphenylphosphine oxide Compound (Compound 25)
Compound 25 structural formula:
adding N-benzyl-alpha- (1,1' -biphenyl) nitrone (0.001 mol), phosphorus diphenoxy (0.0015 mol) and N-hexane (5 ml) into a round-bottom flask with the volume of 10ml in sequence, putting a magnetic stirrer, stirring at 500 revolutions per minute on the magnetic stirrer, reacting for 3 hours at the temperature of 60 ℃, monitoring the reaction by TLC, and distilling the mixed solution under reduced pressure to remove the solvent when no nitrone compound remains to obtain an initial product. The crude product was then purified by recrystallization (solvent: n-hexane/ethyl acetate, 80). The yield thereof was found to be 88%.
The structure of compound 25 was examined by nmr and the results were as follows:
1 H NMR(400MHz,CDCl 3 )δ7.84(dd,J=11.2,7.6Hz,2H),7.71(dd,J=13.8,7.4Hz,2H),7.63(dd,J=10.7,8.0Hz,2H),7.55(d,J=7.5Hz,3H),7.51–7.47(m,6H),7.43(d,J=7.2Hz,4H),7.36–7.33(m,1H),7.29(d,J=7.4Hz,1H),7.25–7.22(m,3H),7.13(dd,J=6.8,2.6Hz,2H),5.08(s,1H),4.12(d,J=13.0Hz,1H),3.67(d,J=13.2Hz,1H). 13 C NMR(101MHz,CDCl 3 )δ141.02,140.56,140.25,136.74,132.72,132.70,132.18,132.12,131.79,131.66,131.58,131.34,131.25,130.89,130.78,129.51,129.38,129.24,129.12,129.09,128.99,128.97,128.88,128.56,128.44,128.38,128.27,128.16,127.95,127.55,127.18,127.14,127.11,126.83,77.48,77.16,76.84,71.31,61.60.
example 26 Synthesis of (1- ((hydroxy) benzylamino) propyl) diphenylphosphine oxide (Compound 26).
Compound 26 has the structural formula:
adding N-benzyl-alpha-ethyl nitrone (0.001 mol), phosphorus diphenoxylate (0.0015 mol) and N-hexane (5 ml) into a round-bottom flask with the volume of 10ml in sequence, putting a magnetic stirrer, stirring at 500 revolutions per minute on the magnetic stirrer, reacting at the temperature of 60 ℃ for 3 hours, monitoring the reaction by TLC, and distilling the mixed solution under reduced pressure to remove the solvent when no nitrone compound remains to obtain an initial product. The crude product was then purified by recrystallization (solvent: n-hexane/ethyl acetate, 80). The yield thereof was found to be 82%.
The structure of the compound 26 is detected by nuclear magnetic resonance, and the results are as follows:
1 H NMR(400MHz,CDCl 3 )δ7.75(ddd,J=11.1,8.3,1.5Hz,4H),7.52–7.40(m,7H),7.21(dd,J=5.0,1.9Hz,3H),7.09–7.03(m,2H),4.25(d,J=13.2Hz,1H),3.99(d,J=13.2Hz,1H),3.64(td,J=7.0,5.2Hz,1H),2.23(ddt,J=14.9,11.4,7.4Hz,1H),1.76(dddd,J=19.3,9.6,7.5,5.2Hz,1H),0.92(t,J=7.5Hz,3H). 13 C NMR(101MHz,CDCl 3 )δ137.48,133.07,132.70,132.67,132.56,132.11,131.92,131.89,131.72,131.69,131.65,131.39,131.30,131.20,130.85,130.74,129.43,129.29,129.06,129.01,128.93,128.73,128.62,128.51,128.31,127.36,66.02,65.21,61.67,61.57,17.29,17.25,13.92,13.84.
EXAMPLE 27 Synthesis of (1- ((hydroxy) benzylamino) butyl) diphenylphosphine oxide Compound (Compound 27)
Compound 27 has the structural formula:
the synthesis process comprises the following steps: adding N-benzyl-alpha-propyl nitrone (0.001 mol), phosphorus diphenoxylate (0.0015 mol) and N-hexane (5 ml) into a round-bottom flask with the volume of 10ml in sequence, placing a magnetic stirrer, placing the magnetic stirrer on a magnetic stirrer for 500 revolutions per minute, stirring at the temperature (60 ℃) for 3 hours, monitoring the reaction by TLC, and distilling the mixed solution under reduced pressure to remove the solvent when no nitrone compound remains to obtain an initial product. The crude product was then purified by recrystallization (solvent: n-hexane/ethyl acetate, 80). The yield thereof was found to be 85%.
The structure of compound 27 was examined by nmr and the results were as follows:
1 H NMR(400MHz,CDCl 3 )δ7.80–7.72(m,4H),7.51–7.47(m,2H),7.44(dt,J=8.1,3.3Hz,4H),7.38(s,1H),7.20(dd,J=5.0,2.0Hz,2H),7.05(dd,J=6.7,2.8Hz,2H),6.40(s,1H),4.24(d,J=13.2Hz,1H),3.97(d,J=13.2Hz,1H),3.73(td,J=7.1,5.1Hz,1H),2.26–2.10(m,1H),1.73–1.60(m,1H),1.51–1.41(m,1H),1.22–1.11(m,1H),0.79(t,J=7.3Hz,3H). 13 C NMR(101MHz,CDCl 3 )δ137.46,133.04,132.69,132.66,132.50,132.08,131.93,131.90,131.71,131.68,131.59,131.43,131.34,131.28,131.19,130.85,130.74,129.38,129.28,129.06,129.00,128.98,128.93,128.70,128.61,128.59,128.50,128.29,127.35,77.48,77.16,76.84,64.24,63.43,61.66,61.57,25.91,25.87,22.26,22.18,14.20,14.07.
EXAMPLE 28 Synthesis of (1- ((hydroxy) benzylamino) isobutyl) diphenylphosphine oxide Compound (Compound 28)
Compound 28 is of the formula:
adding N-benzyl-alpha-isopropyl nitrone (0.001 mol), phosphorus diphenoxylate (0.0015 mol) and N-hexane (5 ml) into a round-bottom flask with the volume of 10ml in sequence, putting a magnetic stirrer, stirring at 500 revolutions per minute on the magnetic stirrer, reacting at the temperature of 60 ℃ for 3 hours, monitoring the reaction by TLC, and distilling the mixed solution under reduced pressure to remove the solvent when no nitrone compound remains to obtain an initial product. The crude product was then purified by recrystallization (solvent: n-hexane/ethyl acetate, 80). The yield thereof was found to be 83%.
The structure of compound 28 was examined by nmr and the results were as follows:
1 H NMR(400MHz,CDCl 3 )δ7.80(dddd,J=11.1,8.4,3.1,1.5Hz,4H),7.62–7.34(m,7H),7.19(dd,J=5.1,2.0Hz,3H),7.04–6.93(m,2H),6.73(s,1H),4.24(d,J=13.2Hz,1H),4.09(d,J=13.2Hz,1H),3.63(dd,J=7.9,4.6Hz,1H),2.45(dpd,J=11.4,6.9,4.6Hz,1H),1.06(dd,J=24.9,6.9Hz,6H). 13 C NMR(101MHz,CDCl 3 )δ137.54,134.71,133.78,132.89,131.70,131.67,131.48,131.45,131.30,131.20,131.05,130.96,130.79,130.67,129.14,129.05,128.99,128.93,128.86,128.62,128.58,128.51,128.46,128.19,127.25,77.38,77.06,76.74,69.12,68.40,62.61,62.54,28.12,28.06,22.23,22.16,21.82,21.78.
example 29 Synthesis of (1- ((hydroxy) benzylamino) pentyl) diphenylphosphine oxide Compound (Compound 29)
Compound 29 has the structural formula:
the synthesis process comprises the following steps: adding N-benzyl-alpha-butyl nitrone (0.001 mol), phosphorus diphenoxylate (0.0015 mol) and N-hexane (5 ml) into a round-bottom flask with the volume of 10ml in sequence, putting a magnetic stirrer, stirring at 500 revolutions per minute on the magnetic stirrer, reacting at the temperature of 60 ℃ for 3 hours, monitoring the reaction by TLC, and distilling the mixed solution under reduced pressure to remove the solvent when no nitrone compound remains to obtain an initial product. Then the primary product is purified by a pulping method (solvent: petroleum ether or normal hexane) to obtain a pure product. The yield thereof was found to be 88%.
The structure of compound 29 was examined by nmr and the results were as follows:
1 H NMR(400MHz,CDCl 3 )δ7.75(tt,J=8.5,2.2Hz,4H),7.51–7.47(m,2H),7.43(dq,J=7.7,3.7Hz,4H),7.37(s,1H),7.20(dd,J=4.9,2.0Hz,3H),7.07–7.04(m,1H),6.46(s,1H),4.24(d,J=13.1Hz,1H),3.96(d,J=13.2Hz,1H),3.70(q,J=6.5Hz,1H),2.20(dtt,J=16.6,11.4,5.7Hz,1H),1.78–1.61(m,1H),1.43(ddt,J=13.9,8.7,5.3Hz,1H),1.24–1.05(m,3H),0.75(t,J=7.2Hz,3H). 13 C NMR(101MHz,CDCl 3 )δ137.47,132.99,132.66,132.63,132.49,132.03,131.88,131.85,131.66,131.63,131.57,131.41,131.33,131.27,131.18,130.81,130.70,129.35,129.27,129.02,128.96,128.93,128.90,128.65,128.61,128.57,128.54,128.49,128.45,128.25,127.30,77.48,77.16,76.84,64.39,63.58,61.58,61.48,31.20,31.12,27.65,26.55,23.28,23.24,22.70,13.80.
EXAMPLE 30 Synthesis of (1- ((hydroxy) benzylamino) -3-methylbutyl) diphenylphosphine oxide Compound (Compound 30)
Compound 30 has the structural formula:
the synthesis process comprises the following steps: adding N-benzyl-alpha-isobutyl nitrone (0.001 mol), phosphorus diphenoxylate (0.0015 mol) and N-hexane (5 ml) into a round-bottom flask with the volume of 10ml in sequence, putting a magnetic stirrer, stirring at 500 revolutions per minute on the magnetic stirrer, reacting at the temperature of 60 ℃ for 3 hours, monitoring the reaction by TLC, and distilling the mixed solution under reduced pressure to remove the solvent when no nitrone compound remains to obtain an initial product. Then the primary product is purified by a pulping method (solvent: petroleum ether or normal hexane) to obtain a pure product. The yield thereof was found to be 93%.
The structure of compound 30 was examined by nmr and the results were as follows:
1 H NMR(400MHz,CDCl 3 )δ7.82–7.75(m,3H),7.69(ddd,J=13.7,8.2,1.4Hz,1H),7.57–7.43(m,7H),7.38(s,1H),7.19(dd,J=5.0,1.9Hz,2H),7.10–7.01(m,2H),4.25(d,J=13.3Hz,1H),3.99(d,J=13.3Hz,1H),3.85(td,J=7.6,4.9Hz,1H),2.13(dddd,J=14.1,10.8,7.8,5.8Hz,1H),1.65–1.39(m,2H),0.84(d,J=6.5Hz,3H),0.71(d,J=6.5Hz,3H). 13 C NMR(101MHz,CDCl 3 )δ137.61,133.14,133.06,132.68,132.65,132.48,132.18,131.94,131.91,131.76,131.74,131.57,131.46,131.38,131.29,130.85,130.74,129.35,129.19,129.05,129.01,128.97,128.92,128.69,128.66,128.58,128.54,128.26,127.30,77.48,77.16,76.84,62.62,61.83,61.61,61.52,32.99,32.95,26.25,26.17,26.07,23.02,22.68,21.93.
EXAMPLE 31 Synthesis of (1- ((hydroxy) benzylamino) phenylpropyl) diphenylphosphine oxide Compound (Compound 31)
Compound 31 has the structural formula:
adding N-benzyl-alpha-phenethyl nitrone (0.001 mol), phosphorus diphenoxylate (0.0015 mol) and N-hexane (5 ml) into a round-bottom flask with the volume of 10ml in sequence, putting a magnetic stirrer, stirring at 500 revolutions per minute on the magnetic stirrer, reacting at the temperature of 60 ℃ for 3 hours, monitoring the reaction by TLC, and distilling the mixed solution under reduced pressure to remove the solvent when no nitrone compound remains to obtain an initial product. Then the primary product is purified by a pulping method (solvent: petroleum ether or normal hexane) to obtain a pure product. The yield thereof was found to be 82%.
The structure of the compound 31 is detected by nuclear magnetic resonance, and the results are as follows:
1 H NMR(400MHz,CDCl 3 )δ7.76–7.64(m,5H),7.55–7.52(m,2H),7.50–7.42(m,4H),7.29(s,1H),7.26–7.19(m,5H),7.07–7.01(m,2H),6.97(d,J=1.8Hz,1H),6.68–6.36(m,1H),4.27(d,J=13.1Hz,1H),4.00(d,J=13.1Hz,1H),3.81–3.72(m,1H),2.85(t,J=4.2Hz,1H),2.65–2.54(m,2H),2.09–1.96(m,1H). 13 C NMR(101MHz,CDCl 3 )δ132.95,132.70,132.04,131.80,131.42,131.35,131.32,131.26,130.90,130.79,129.44,129.10,129.03,128.97,128.84,128.75,128.72,128.66,128.59,128.42,127.48,126.41,126.19,62.76,61.87,61.78,34.22,34.14,26.09,26.04.
example 32 Synthesis of ((hydroxy (methyl) amino) (phenyl) methyl) diphenylphosphine oxide Compound (Compound 32)
Compound 32 has the structural formula:
the synthesis process comprises the following steps: adding N-methyl-alpha-phenyl nitrone (0.001 mol), phosphorus diphenoxylate (0.0015 mol) and N-hexane (5 ml) into a round-bottom flask with the volume of 10ml in sequence, putting a magnetic stirrer, stirring at 500 revolutions per minute on the magnetic stirrer, reacting at the temperature of 60 ℃ for 3 hours, monitoring the reaction by TLC, and distilling the mixed solution under reduced pressure to remove the solvent when no nitrone compound remains to obtain an initial product. The crude product was then purified by recrystallization (solvent: n-hexane/ethyl acetate, 80). The yield thereof was found to be 88%.
The structure of compound 32 was examined by nmr and the results were as follows:
1 H NMR(400MHz,CDCl 3 )δ7.97–7.86(m,2H),7.54–7.41(m,5H),7.31(ddd,J=8.8,7.0,1.6Hz,3H),7.25–7.05(m,6H),4.61(d,J=5.3Hz,1H),2.59(s,3H). 13 C NMR(101MHz,CDCl 3 )δ133.39,132.41,132.12,131.84,131.81,131.68,131.62,131.56,131.53,131.49,131.48,131.26,131.20,130.70,128.63,128.52,128.34,128.33,128.18,128.14,128.02,46.75,46.64.
example 33 Synthesis of ((hydroxy (methyl) amino) (4-methylphenyl) methyl) diphenylphosphine oxide Compound (Compound No. 33)
Compound 33 has the structural formula:
adding N-methyl-alpha- (4-methylphenyl) nitrone (0.001 mol), phosphorus diphenoxy (0.0015 mol) and N-hexane (5 ml) into a round-bottom flask with the volume of 10ml in sequence, adding a magnetic stirrer, stirring every minute at 500 revolutions per minute on the magnetic stirrer, reacting for 3 hours at the temperature of 60 ℃, monitoring the reaction by TLC, and when no nitrone compound remains, distilling the mixed solution under reduced pressure to remove the solvent to obtain an initial product. The crude product was then purified by recrystallization (solvent: n-hexane/ethyl acetate, 80). The yield thereof was found to be 92%.
The structure of compound 33 was examined by nmr and the results are as follows:
1 H NMR(400MHz,CDCl 3 )δ7.88(ddd,J=11.1,8.2,1.5Hz,2H),7.55–7.45(m,5H),7.37–7.32(m,1H),7.25(d,J=5.7Hz,2H),7.21–7.16(m,2H),6.98(d,J=7.8Hz,2H),6.76(s,1H),4.53(d,J=5.9Hz,1H),2.55(s,3H),2.25(s,3H). 13 C NMR(101MHz,CDCl 3 )δ131.66,131.64,131.57,131.24,128.92,128.65,128.53,128.18,128.07,77.48,77.16,76.84,46.55,46.43,21.29.
EXAMPLE 34 Synthesis of (((hydroxy) benzylamino) (phenyl) methyl) (3,5-xylyl) phosphine oxide (Compound 34)
Compound 34 has the structural formula:
the synthesis process comprises the following steps: adding N-benzyl-alpha-phenyl nitrone (0.001 mol), 3,5-dimethylphenyl oxyphosphorus (0.0015 mol) and N-hexane (5 ml) into a round-bottom flask with the volume of 10ml in sequence, putting a magnetic stirrer, stirring at 500 revolutions per minute on the magnetic stirrer, reacting for 3 hours at the temperature (60 ℃), monitoring the reaction by TLC, and distilling the mixed solution under reduced pressure to remove the solvent when no nitrone compound remains to obtain an initial product. The crude product was then purified by recrystallization (solvent: n-hexane/ethyl acetate, 80). The yield thereof was found to be 75%.
The structure of compound 34 was examined by nmr and the results were as follows:
1 H NMR(400MHz,CDCl 3 )δ7.30(dddd,J=17.2,7.0,3.4,2.0Hz,5H),7.15–7.10(m,6H),7.07–6.98(m,3H),6.86(dd,J=11.4,1.6Hz,2H),6.78(s,1H),4.41(d,J=8.0Hz,1H),3.94(d,J=13.1Hz,1H),3.49(d,J=13.2Hz,1H),2.24(s,6H),2.01(s,6H). 13 C NMR(101MHz,CDCl 3 )δ138.15,138.03,137.76,137.64,136.95,133.54,133.51,133.27,131.99,131.93,129.45,129.38,129.17,129.12,129.09,128.98,128.89,128.75,128.59,128.35,128.28,128.24,128.03,127.45,77.48,77.16,76.84,21.53,21.24.
example 35 Synthesis of (2-hydroxy-1,2,3,4-tetrahydroisoquinolin-1-yl) diphenylphosphine oxide (Compound 35)
Compound 35 is of the formula:
the synthesis process comprises the following steps: adding 3,4-dihydroisoquinoline-2-oxide (0.001 mol), phosphorus diphenoxylate (0.0012 mol) and n-hexane (5 ml) into a round bottom flask with the volume of 10ml in sequence, adding a magnetic stirrer, stirring at 500 revolutions per minute on the magnetic stirrer, reacting at the temperature of 60 ℃ for 5 hours, monitoring the reaction by TLC, and distilling the mixed solution under reduced pressure to remove the solvent when no nitrone compound remains to obtain an initial product. The crude product was then purified by recrystallization (solvent: n-hexane/ethyl acetate, 80). The yield thereof was found to be 85%.
The structure of compound 35 was examined by nmr and the results are as follows:
1 H NMR(500MHz,CDCl 3 )δ7.87–7.78(m,4H),7.57–7.45(m,6H),7.24–7.14(m,2H),7.12(dd,J=4.8,1.2Hz,2H),4.60(p,J=6.0Hz,1H),4.40(ddd,J=11.5,6.0,1.0Hz,1H),3.99(d,J=6.4Hz,1H),2.99(dddd,J=14.8,8.0,5.7,1.1Hz,1H),2.77(dddd,J=14.8,7.9,5.7,0.9Hz,1H),2.05(ddt,J=13.7,7.9,5.7Hz,1H),1.87(ddt,J=13.6,8.1,5.7Hz,1H). 13 C NMR(125MHz,CDCl 3 )δ134.88,133.46,132.56,131.76,131.30,129.35,128.59,127.21,126.92,126.68,70.81,48.93,28.60,27.28.
example Synthesis of ((2R, 3S, 4R) -2,3-bis (benzyloxy) -4- ((benzyloxy) methyl) -5-hydroxycyclopentyl) diphenyl oxide (Compound 36)
Compound 36 is of the formula:
the synthesis process comprises the following steps: a round bottom flask with the volume of 10ml is sequentially added with (2S, 3S, 4S) -3,4-bis (benzyloxy) -2- ((benzyloxy) methyl) -3,4-dihydro-2H-pyrrole 1-oxide (0.001 mol), diphenoxy phosphorus (0.0012 mol) and n-hexane (5 ml), a magnetic stirrer is placed in the round bottom flask, the round bottom flask is placed on the magnetic stirrer for 500 revolutions per minute, the temperature (60 ℃) is reacted for 5 hours, the reaction is monitored by TLC, when no nitrone compound is left, the mixed solution is decompressed and distilled to remove the solvent to obtain an initial product. The crude product was then purified by recrystallization (solvent: n-hexane/ethyl acetate, 80). The yield thereof was found to be 88%.
The structure of compound 36 was examined by nmr and the results were as follows:
1 H NMR(500MHz,CDCl 3 )δ7.87(ddt,J=13.3,6.8,1.4Hz,4H),7.56–7.48(m,2H),7.46(tdd,J=8.0,4.0,1.0Hz,4H),7.34(tddd,J=5.0,3.3,2.3,1.2Hz,4H),7.34–7.24(m,11H),4.73(dd,J=6.6,5.9Hz,1H),4.62(ddt,J=12.1,6.0,0.9Hz,2H),4.56–4.49(m,2H),4.49–4.38(m,3H),4.29(dd,J=5.9,4.2Hz,1H),4.07(dd,J=11.4,6.6Hz,1H),3.83(dd,J=10.6,4.6Hz,1H),3.69(dd,J=10.5,4.7Hz,1H),3.31(q,J=4.5Hz,1H). 13 C NMR(125MHz,CDCl 3 )δ137.82,137.59,137.42,131.79,130.98,130.72,128.62,128.43,128.41,128.40,128.22,128.13,128.10,128.08,128.07,127.99,127.95,81.64,81.29,73.30,72.87,72.39,67.00,61.80,58.93.
example 37 ((3R, 4S, 5S) -3,4-bis (benzyloxy) -5- ((S) -1,2-bis (benzyloxy) ethyl) -1-hydroxypyrrolidin-2-yl) diphenylphosphine oxide
Compound 37 has the structural formula:
the synthesis process comprises the following steps: a round bottom flask with the volume of 10ml is sequentially added with (2S, 3S, 4S) -3,4-bis (benzyloxy) -2- ((S) -1,2-bis (benzyloxy) ethyl) -3,4-dihydro-2H-pyrrole-1-oxide (0.001 mol), diphenoxy phosphorus (0.0012 mol) and n-hexane (5 ml), a magnetic stirrer is placed in the round bottom flask, the round bottom flask is placed on a magnetic stirrer for 500 revolutions per minute to be stirred, the temperature (60 ℃) is reacted for 8 hours, TLC monitors the reaction, when no nitrone compound remains, the mixed solution is decompressed and distilled to remove the solvent to obtain an initial product. The crude product was then purified by recrystallization (solvent: n-hexane/ethyl acetate, 80). The yield thereof was found to be 82%.
The structure of compound 37 was examined by nmr and the results were as follows:
1 H NMR(500MHz,CDCl 3 )δ7.90–7.81(m,4H),7.55–7.48(m,2H),7.46(tdd,J=7.9,3.9,1.0Hz,4H),7.38–7.24(m,20H),4.93(dd,J=6.6,5.9Hz,1H),4.77(s,1H),4.72(dt,J=12.1,1.1Hz,1H),4.62(dt,J=12.1,1.1Hz,1H),4.58–4.50(m,2H),4.52–4.45(m,2H),4.42(ddt,J=15.9,12.1,1.0Hz,2H),4.25(t,J=5.9Hz,1H),4.07(dd,J=11.5,6.6Hz,1H),3.80–3.70(m,2H),3.56(dd,J=11.0,5.9Hz,1H),3.23(dd,J=6.2,5.3Hz,1H). 13 C NMR(125MHz,CDCl 3 )δ137.79,137.76,137.50,137.43,131.74,130.94,130.67,128.63,128.46,128.45,128.43,128.41,128.39,128.27,128.24,128.21,128.18,128.15,128.14,128.07,128.01,128.00,81.98,80.73,74.53,73.60,72.94,72.50,71.18,70.95,62.88,61.85.
example 38 ((3R, 4S, 5R) -3,4-bis (benzyloxy) -5- ((S) -1,2-bis (benzyloxy) ethyl) -1-hydroxypyrrolidin-2-yl) diphenylphosphine oxide
Compound 38 structural formula is:
the synthesis process comprises the following steps: a round bottom flask with the volume of 10ml is sequentially added with (2R, 3S, 4S) -3,4-bis (benzyloxy) -2- ((S) -1,2-bis (benzyloxy) ethyl) -3,4-dihydro-2H-pyrrole-1-oxide (0.001 mol), diphenoxy phosphorus (0.0012 mol) and n-hexane (5 ml), a magnetic stirrer is placed in the round bottom flask, the round bottom flask is placed on a magnetic stirrer for 500 revolutions per minute to be stirred, the temperature (60 ℃) is reacted for 8 hours, TLC monitors the reaction, when no nitrone compound remains, the mixed solution is decompressed and distilled to remove the solvent to obtain an initial product. The crude product was then purified by recrystallization (solvent: n-hexane/ethyl acetate, 80). The yield thereof was found to be 80%.
The structure of compound 38 was examined by nmr and the results are as follows:
1 H NMR(500MHz,CDCl 3 )δ7.89(ddt,J=13.2,6.8,1.4Hz,4H),7.55–7.48(m,2H),7.46(tdd,J=7.9,3.9,1.1Hz,4H),7.38–7.24(m,20H),4.98(dd,J=6.6,5.9Hz,1H),4.62(dt,J=12.0,1.1Hz,1H),4.58–4.47(m,4H),4.51–4.37(m,3H),4.35(dt,J=12.1,1.0Hz,1H),4.16(dd,J=5.8,5.1Hz,1H),4.07(dd,J=11.6,6.6Hz,1H),3.80–3.69(m,2H),3.49(dd,J=11.3,5.4Hz,1H),3.27(t,J=5.2Hz,1H).13C NMR(125MHz,CDCl 3 )δ137.79,137.76,137.50,137.43,131.74,130.94,130.67,128.63,128.46,128.45,128.43,128.41,128.39,128.27,128.24,128.21,128.18,128.15,128.14,128.07,128.01,128.00,81.98,80.73,74.53,73.60,72.94,72.50,71.18,70.95,62.88,61.85.
example 38 ((3R, 4S,5S, 6R) -3,4,5-tris (benzyloxy) -6- ((benzyloxy) methyl) -1-hydroxypiperidin-2-yl) diphenylphosphine oxide
Compound 39 has the structural formula:
the synthesis process comprises the following steps: a round bottom flask with the volume of 10ml is sequentially added with (2R, 3S,4S, 5S) -3,4,5-tri (benzyloxy) -2- ((benzyloxy) methyl) -2,3,4,5-tetrahydropyridine-1-oxide (0.001 mol), diphenoxy phosphorus (0.0012 mol) and n-hexane (5 ml), a magnetic stirrer is placed in the round bottom flask, the round bottom flask is placed on the magnetic stirrer for 500 revolutions per minute, the temperature (60 ℃) is reacted for 5 hours, the reaction is monitored by TLC, when no nitrone compound is left, the mixed solution is decompressed and distilled to remove the solvent to obtain an initial product. The crude product was then purified by recrystallization (solvent: n-hexane/ethyl acetate, 80). The yield thereof was found to be 85%.
The structure of compound 39 was examined by nmr and the results are as follows:
1 H NMR(500MHz,CDCl 3 ))δ7.86–7.77(m,5H),7.55–7.48(m,2H),7.45(tdd,J=7.8,3.9,1.0Hz,4H),7.40–7.32(m,6H),7.35–7.24(m,15H),4.80(ddt,J=11.9,3.5,1.0Hz,2H),4.63(dt,J=12.1,1.0Hz,2H),4.51(dt,J=12.1,0.9Hz,1H),4.48–4.36(m,4H),4.04(dd,J=11.5,6.6Hz,1H),3.99(dd,J=7.6,5.2Hz,1H),3.86(dd,J=5.2,3.6Hz,1H),3.80(dd,J=10.5,6.3Hz,1H),3.74(dd,J=10.5,6.3Hz,1H),3.16(td,J=6.3,3.7Hz,1H). 13 C NMR(125MHz,CDCl 3 ))δ138.39,137.73,137.51,137.43,131.74,130.69,130.67,128.63,128.46,128.45,128.43,128.41,128.39,128.27,128.24,128.21,128.18,128.17,128.15,128.07,128.01,128.00,76.61,75.83,75.42,73.24,72.40,71.92,71.80,71.75,64.30,57.25.
example 40
The in vitro anti-tumor activity test of the synthetic compound and the cytotoxicity test on normal cells.
The experimental principle is as follows: the tetrazolium salt (MTT) reduction method was tested in vitro. Camptothecin (Camptothecin) was selected as a positive control.
Cell lines: human lung adenocarcinoma cells (A549), human breast cancer cells (MCF-7), and mouse lung epithelial cells (TC-1).
The experimental method comprises the following steps:
prepared at a concentration of 1X 10 5 mu.g/mL of the cell suspension, adding to a 96-well plate at 100. Mu.L per well, at 37 ℃,5% CO 2 Incubate in incubator for 24h.
The test substances with different concentrations are added into a 96-well plate of cultured tumor cells and normal cells, and the culture is continued for 24 hours and observed under an inverted microscope.
The culture medium was discarded, and 100. Mu.L of 0.05% MTT application solution was added to each well, followed by culture for 4 hours.
The culture solution was discarded, 100. Mu.L of DMSO was added to each well, formazan crystals were dissolved by shaking for 5min, and the absorbance (OD value) of the cells was measured at 490 nm.
The experimental data processing method comprises the following steps:
the absorbance of the cells in the wells without drug was used as the absorbance (OD value) of the blank control group, and the calculation formula was as follows:
inhibition (%) = (blank OD average value-sample OD average value)/blank OD average value x 100%,
and (3) obtaining a concentration and time-growth inhibition rate curve according to the growth inhibition rate mapping at different time and different dosage, adopting GraphPad Prism 9.0 software to map, and calculating the half inhibition concentration IC50 of the target compound to the two tumor cells by using the software. See table below.
The results in the table show that the compound has a certain inhibiting effect on A549/MCF-7 tumor cells, and has no obvious toxicity on normal cells TC-1, which indicates that the compound has potential medicinal value and is expected to be used for preparing various anti-cancer medicaments.
The above description is only for the specific embodiments of the present invention, but the scope of the present invention is not limited thereto, and any person skilled in the art can easily conceive of the changes or substitutions within the technical scope of the present invention, and all the changes or substitutions should be covered within the scope of the present invention. Therefore, the protection scope of the present invention shall be subject to the protection scope of the appended claims.
Claims (10)
1. A method for preparing alpha- (hydroxyl amino) diaryl phosphine oxide by nitrone is characterized in that nitrone shown in formula (2) and diaryl phosphine oxide shown in formula (3) are used as raw materials to react under heating condition to obtain alpha- (hydroxyl amino) diaryl phosphine oxide shown in formula (1),
wherein R is 1 Is selected from C 1 -C 10 Alkyl, furyl, thienyl, C 5 -C 6 One of alkylene ring, phenyl group or aromatic group,
R 2 is selected from C 1 -C 10 Alkyl of (C) 5 -C 6 One of an alkylene ring, a substituted or unsubstituted phenyl group;
R 3 、R 4 each independently selected from phenyl and aryl.
2. A process for preparing an α - (hydroxyamino) diarylphosphine oxide from a nitrone according to claim 1, wherein R is 1 Selected from ethyl, propyl, isopropyl, butyl, isobutyl, cyclohexyl, halophenyl, alkyl-substituted phenyl, methoxy-substituted phenyl, methylamino-substituted phenyl, acetoxy-substituted phenyl, naphthyl, or biphenyl.
3. A process for preparing an α - (hydroxyamino) diarylphosphine oxide from a nitrone according to claim 1, wherein R is 2 Selected from ethyl, propyl, isopropyl, butyl, isobutyl, cyclohexyl, phenyl or benzyl, preferably, R 1 、R 2 Each independently selected from C 5 -C 6 An alkylene ring.
4. The method for preparing alpha- (hydroxyamino) diarylphosphine oxide from nitrone according to claim 1, wherein the ratio of nitrone to diarylphosphine oxide is 1:1-2.
5. A method for preparing α - (hydroxyamino) diarylphosphine oxide from nitrone according to claim 1, wherein nitrone, diarylphosphine oxide compound is used as raw material, water or n-hexane is used as solvent, and preferably, the amount of water and n-hexane is 50-100 times of the amount of nitrone.
6. A process for preparing α - (hydroxyamino) diarylphosphine oxide from nitrone according to claim 1, wherein the reaction time is 1-3 hours.
7. The method for preparing alpha- (hydroxyamino) diarylphosphine oxide from nitrone according to claim 1, wherein nitrone represented by formula (2) and diarylphosphine oxide compound represented by formula (3) are used as raw materials, and the reaction is carried out at 60-90 ℃.
8. The method for preparing α - (hydroxyamino) diarylphosphine oxide from nitrone according to claim 1, wherein α - (hydroxyamino) diarylphosphine oxide represented by formula (1) is obtained and then purified by the steps of: removing solvent, and purifying by recrystallization or pulping to obtain pure product.
9. A process for the preparation of α - (hydroxyamino) diarylphosphine oxides from nitrones according to claim 8, wherein the step of recrystallization is: dissolving the product by using ethyl acetate, separating out the product by using normal hexane, and performing suction filtration to obtain a pure product; or
The pulping steps are as follows: firstly, adding normal hexane into the product, quickly stirring to dissolve impurities, and carrying out suction filtration to obtain a pure product.
10. Use of an α - (hydroxyamino) diarylphosphine oxide prepared by the method of claim 1 in the preparation of an anti-tumor medicament.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202211267152.9A CN115583970A (en) | 2022-10-17 | 2022-10-17 | Method for preparing alpha- (hydroxy amino) diaryl phosphine oxide from nitrone |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202211267152.9A CN115583970A (en) | 2022-10-17 | 2022-10-17 | Method for preparing alpha- (hydroxy amino) diaryl phosphine oxide from nitrone |
Publications (1)
Publication Number | Publication Date |
---|---|
CN115583970A true CN115583970A (en) | 2023-01-10 |
Family
ID=84779777
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202211267152.9A Pending CN115583970A (en) | 2022-10-17 | 2022-10-17 | Method for preparing alpha- (hydroxy amino) diaryl phosphine oxide from nitrone |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN115583970A (en) |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5976858A (en) * | 1994-02-25 | 1999-11-02 | Arris Pharmaceuticals | Irreversible cysteine protease inhibitors containing vinyl groups conjugated to electron withdrawing groups |
US20020103203A1 (en) * | 2000-01-21 | 2002-08-01 | Bender Steven Lee | Amide compounds and pharmaceutical compositions for inhibiting protein kinases, and methods for their use |
US20160115130A1 (en) * | 2013-06-17 | 2016-04-28 | Centre National De La Recherche Scientifique | Alkoxyamines for the treatment of cancers |
CN108203449A (en) * | 2016-12-16 | 2018-06-26 | 天地人和生物科技有限公司 | A kind of reversible proton pump inhibitor and its preparation method and application |
CN111892627A (en) * | 2020-08-20 | 2020-11-06 | 遵义医科大学 | Green synthesis method of alpha-aminophosphonium oxide |
-
2022
- 2022-10-17 CN CN202211267152.9A patent/CN115583970A/en active Pending
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5976858A (en) * | 1994-02-25 | 1999-11-02 | Arris Pharmaceuticals | Irreversible cysteine protease inhibitors containing vinyl groups conjugated to electron withdrawing groups |
US20020103203A1 (en) * | 2000-01-21 | 2002-08-01 | Bender Steven Lee | Amide compounds and pharmaceutical compositions for inhibiting protein kinases, and methods for their use |
US20160115130A1 (en) * | 2013-06-17 | 2016-04-28 | Centre National De La Recherche Scientifique | Alkoxyamines for the treatment of cancers |
CN108203449A (en) * | 2016-12-16 | 2018-06-26 | 天地人和生物科技有限公司 | A kind of reversible proton pump inhibitor and its preparation method and application |
CN111892627A (en) * | 2020-08-20 | 2020-11-06 | 遵义医科大学 | Green synthesis method of alpha-aminophosphonium oxide |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA1072112A (en) | Benzylidene derivatives | |
JP2710654B2 (en) | 1,2-bis (aminomethyl) cyclobutane-platinum complex compound, method for producing the same, drug containing the compound having antitumor activity, and method for producing the same | |
JP5052420B2 (en) | Novel bis-platinum complexes with polyamine ligands as antitumor agents | |
US4661516A (en) | Diaminocyclohexane platinum complexes | |
CA1171425A (en) | Organic platinum complexes and uses | |
EP0219936A1 (en) | Novel platinum complexes | |
JP2008303216A (en) | New bis-platinum complex with polymethylene derivative as ligand having antitumor activity | |
KR100239787B1 (en) | Trinuclear cationic platinum complexes having antitumour activity and pharmaceutical compositions containing them | |
EP1876182B1 (en) | Phosphine transition metal complex, process for producing the same and anticancer drug containing the same | |
EA015619B1 (en) | Bis-platinum complexes with antitumor activity | |
CN115583970A (en) | Method for preparing alpha- (hydroxy amino) diaryl phosphine oxide from nitrone | |
EP0176005B1 (en) | Novel platinum complexes | |
JP2004502696A (en) | Ruthenium (II) compounds for cancer treatment | |
CN113501783B (en) | Erianin heterocyclic derivative and preparation method and application thereof | |
CN112175014B (en) | Nitric oxide donor type tetravalent platinum derivative, preparation method and medical application thereof | |
KR20230002110A (en) | Method of manufactuing N-acyl derivative, composition and medical or agriculture supplies comprising the same | |
HU215436B (en) | Process for preparing n-[(4,5-dihydroxi-9,10-dihydro-9,10-dioxo-2-anthracene-yl)carbonyl]amino acids and pharmaceutical compositions containing them as active agent | |
JPS62174092A (en) | Platinum ligand compound and its production | |
US5037812A (en) | Tumor cell growth-inhibiting pharmaceutical compositions containing phosphino-hydrocarbon-gold, silver or copper complexes | |
KR20000070057A (en) | Method for synthesis of rhizoferrin | |
Nechipadappu et al. | Solid-state versatility in tranexamic acid drug: structural and thermal behavior of new salts and cocrystals | |
CN114436925B (en) | M-diphenol ether compound, preparation method and application thereof | |
CN115197113B (en) | Combretastatin A-4 derivative containing thiourea structure, preparation method and application thereof | |
CN1558909A (en) | Supermolecular carboplatinum derivatives, their preparation method, and pharmaceutical composition containing them as active ingredient and applications of the composition | |
JPH04264092A (en) | N,o-spirocyclic derivative of cyclotriphosphazene and preparation and use thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination |